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(57) ABSTRACT 
Compounds, known as heteroarotinoids, having varying 
abilities to inhibit growth of certain cancerous cells, induce 
normal cell differentiation, and induce apoptosis or death of 






Ar and Ar' denote aryl substituents, and wherein at least 
one of said aryl substituents comprises an aromatic ring 
having at least one heteroatom in a fused, partially 
saturated ring; 
W denotes O or S; and 
Q denotes H or i-C3 H7 . 
27 Claims, 2 Drawing Sheets 





C 10 4-HPR 
0 
J-
UJ 1 1 


















5 10 15 20 25 30 
DA VS OF TREATMENT 
Fig. I 
U.S. Patent Jul. 1, 2003 Sheet 2 of 2 US 6,586,460 Bl 
I I I I I 
I •••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••••• 
1 :::t::::::::::?::t?:::f n !;:::::?t::}f :::t:t:{ ::! ::::?t:?::t::tt:::::::::::t 
I :•:•:•:::•:::•:•:•:::•:::•:•:•:::•:::•:::::•:•:•:• :•:•:•~;:•:::•:•:•:•:•:•:::•:::•:•:•:•:•:j•::::•:::::•:::❖:::::•:•:::•:•:;.::•:::::•:::•:• 
I I 
I 
I I I 
:-:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•+·••:•:•:•:•:•:•:•:•:•:•:•:•:❖:•:•:•:•:•:•:•:••••:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•.•··••:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•.-. 
1 ~ttt::tt:t::;:::t::t:mt::t:tt:t;:tttmtrt::t:f :;:::::tt :f::::t::t:::::::t: ..................................................................................................... ........... . . . . ... . ................... . 
I 
I I I 
~--.... ~:,,..(.,.:, ... ,,, ,.::,..:::""::""':!:"",,""':::""::....,mm• • ....... 1. ...... ,,. ....... ,,. .. t,. • • .. ,. } 
· ..... ·::::::::::::::::::::::•····::::::::::::::::::::::. 
:::::::::r·::::::::::::::::::-:::::::::::::::-::::::::.··,:::::::::::::::-::::::::::::::::::::::::::::::::: 
, __ -,1;:::::::::1·:::::::::::::::::::::::::::::::::::::::::::_·.-,::::::::::::::::::::::::::::::::::::::::::::::::: 
I ::::::::::1.::::::::::::::::::::::::::::::::::::::::::::::::!::::::::::::::::::::::::::::::::;:;:;:;:;:;:::;:;:::: ~.. ' .............. '... .. ... . . .... .. . .. . . .. . . .. .. ... 
::::::: .' :::::::.·: ::::. ::::::::::::::::::::::::... ·:::::::: ::::::::::::::::. :::::::: :::::::::::::: :::::. ::: ::::.·: :::::::::::::::::. 
N 





: . •:• .. •:• .. •:•:• .. •: ..• i:. •:•:•:• ...... •:•: .: . •:• .. :+ . ::•. •:•:•:•:•:•:•:•:•:•. •:•:• .. . ...l • .... •:•:•:•:•:•:•:• ......... .-·,: ... •:• .. •:•:• .. •:•. •:• ...•..... 
...................................................... ······················································ 
:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•,:::c:::•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:-:,1 ,•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•i:·:::•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:• Vl 
::::::::::::::::::::::::::::::::::::::::::::::f.:r.:":·:·:::::::::::::::::::::::::::::::::::::::::::::.:~:::::::::::::::::::::::::::::::::::::::::::··1:·:·:·:::::::::::::::::::::::::::::::::::::::::::::: < 
:::::::::::::::::::-:::::::::::-:::-:::::::::-f::r::·:·:::::::::::::::::::::::::::::::::::::::::::,,·'.::::::::::::::::::::::::::::::::::::::::::::··,:·:::•:::::.:•:::.:•:•:•:•:•:•:•:•:•:•:•:•:•:•:•:• < 





I I I 












US 6,586,460 Bl 
1 
HETEROAROTINOIDS CONTAINING UREA 
OR THIOUREA LINKER 
2 
retinoids, including the few heteroarotinoids known, are 
found in five treatises, namely "Chemistry and Biology of 
Synthetic Retiniods ", by M. I. Dawson and W. H. Okamura, 
editors, CRC Press: Boca Raton, Fla., 1990, "The STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH 
The Government of the United States of America has 
certain rights in this invention pursuant to Grant No. 5 R0l 
CA73639-03 awarded by the National Institutes of Health 
and/or Grant No. 5 R0l CA77711-03 awarded by the 
National Cancer Institute. 
5 Retinoids", Volumes I and II, by M. B. Sporn,A. B. Roberts, 
and D.S. Goodman, editors, Academic Press: Orlando, Fla., 
1984, "The Retinoids", 2nd Edition, by M. B. Sporn, A. B. 
Roberts, and D. S. Goodman, editors, Raven Press: New 
York, N.Y., 1994, and "Retinoids", Fifth Edition, Vol. 3, by 
BACKGROUND OF INVENTION 
1. Field of the Invention 
10 M. I. Dawson, Chp 44, in Burger's Medicinal Chemistry and 
Drug Discovery, M. E. Wolff, editor, J. Wiley and Sons, Inc., 
New York, 1996. 
More recent work in the general area includes: Journal of 
Medicinal Chemistry, 1999, Vol. 42, pages 3602-3614 
This invention relates to anticancer compositions in terms 
of the inhibition of growth of certain cancerous cell lines and 
in terms of apoptosis or programmed ( or induced) cancer 
cell death. Specifically, the invention relates to certain 
heteroarotinoids and derivatives thereof. 
15 entitled "Synthesis, Structure-Activity Relationships, and 
RARy-Ligand Interactions of Nitrogen Heteroarotinoids" by 
A. Dhar, S. Liu, J. Klucik, K. D. Berlin, M. M. Madler, S. 
Lu, R. T. Ivey, D. Zacheis, C. W. Brown, E. C. Nelson, P. J. 
Birckbichler, and D. M. Benbrook and Journal of Medicinal 
2. Background 
Retinoids (vitamin A and derivatives thereof) is a name 
associated with a family of compounds both of natural and 
synthetic origin. There is significant interest in such mol-
ecules because of the observed strong anticancer activity in 
20 Chemistry, 1999, Vol. 42, pages 4434-4445, entitled "Het-
eroarotinoids Inhibit Head and Neck Cancer Cell Lines in 
vitro and in vivo Through Both RAR and RXR Retinoic 
Acid Receptors" by D. Zacheis, A. Dhar, S. Lu, M. M. 
Madler, J. Klucik, C. W. Brown, S. Liu, F. Clement, S. 
25 Subramanian, G. M. Weerasekare, K. D. Berlin, M.A. Gold, 
J. R. Houch, Jr., K. R. Fountain, and D. M. Benbrook. a number 
of assays including the hamster tracheal organ 
culture (TOC) assay, the omithine decarboxylase (ODC) 
assay, and with HL-60 cells (human leukemic cell line). 
Heteroarotinoids are a group of derivatives that contain an 
aromatic ring and at least one heteroatom in a fused, 30 
partially saturated ring bonded to an aromatic ring. 
Examples of heteroarotinoids and the activity of such in 
the assays cited above are found in several papers such as: 
Journal of Medicinal Chemistry, 1985, Vol. 28, pages 
116-124, entitled "Synthesis and Characterization of 35 
Selected Heteroarotinoids-Pharmacological Activity as 
Assessed in Vitamin A Deficient Hamster Tracheal Organ 
Cultures-Single Crystal X-ray Diffraction Analysis of 4,4-
Dimethylthiochrom-6-yl Methyl Ketone-1,1-Dioxide and 
Ethyl (E)-p-[2-( 4,4-Dimethylthiochroma-6-yl)propenyl] 40 
benzoate", by K. M. Waugh, K. D. Berlin, W. T. Ford, E. M. 
Holt, J. P. Carrol, P. R. Schamber, and L. J. Schiff; Journal 
of Medicinal Chemistry, 1987, Vol. 30, pages 1174--1480, 
entitled "Heteroarotinoids. Synthesis, Characterization, and 
Biological Activity in Terms of an Assessment of these 45 
Systems to Inhibit the Induction of Ornithine Decarboxylase 
Activity and to Induce Terminal Differentiation of HL-60 
cells", by L. W. Spruce, S. N. Rajadhyaksha, K. D. Berlin, 
J. B Gale, E.T. Miranda, W. T. Ford, E. C. Blossey, A. K. 
Verma, M. B. Hossain, D. van der Helm, and T. R. Breitman; 50 
and Journal of Medicinal Chemistry, 1991, Vol. 34, pages 
430---439, entitled "Novel Heteroarotinoids: Synthesis and 
Biological Activity", by L. W. Spruce, J. B. Gale, K. D. 
Berlin, A. K. Verma, T. R. Breitman, X. Ji, and D. van der 
Helm. 55 
Another report entitled "Heteroarotinoids; Crystal and 
Molecular Structure Analysis of Methyl (z)- and Methyl 
(E)-4-[2-( 4,4-Dime thy lthiochroman-6-y 1 )-1-propen y 1] 
benzoate", in the journal entitled Structural Chemistry, 
1991, Vol. 2, pages 515-522, by W. J. Welsh, V. Cody, K. 60 
Suwinska, K. D. Berlin, S. N. Radjadhyaksha, S. 
Subramanian, and A. K. Verma, contains background data 
pertinent to the invention as well. Other background infor-
mation on heteroarotinoids is found in U.S. Pat. No. 4,826, 
984 (May 2, 1989), U.S. Pat. No. 4,883,254 (May 23, 1989) 65 
and U.S. Pat. No. 4,997,276 (Dec. 11, 1990). Summaries of 
the biochemistry, chemistry, and prior biological activity of 
The heteroarotinoids described and claimed herein have 
not been, to the knowledge of the inventors, previously 
described in either the patent or literature art. As will be 
seen, the inventive heteroarotinoids significantly differ both 
in structure and activity as compared to known compounds. 
No assertion is made that the inventive heteroarotinoids 
activate the common retinoid receptors. 
SUMMARY OF THE INVENTION 
The present invention involves the synthesis and use of 
certain unusual heteroarotinoids which have varying abili-
ties to inhibit growth of certain cancerous cells, induce 
normal cell differentiation, and induce apoptosis or death of 
cancerous cells. The inventive structures consist of a three 
atom urea or thiourea linker group with aryl substituents, 
one on each end of the group and bonded to each of the 
nitrogen atoms. One of the aryl substituents has at least one 
heteroatom in a fused, partially saturated ring. Thus, the 
inventive heteroarotinoids have in common the basic 
molecular unit shown below, wherein each aryl substituent 






The inventive heteroarotinoids appear to be much less 
toxic than endogenous and synthetic retinoid standards, e.g. 
trans-retinoic acid, 9-cis-retinoic acid, 13-cis-retinoic acid, 
etretinate, acitretin, and 4-HPR, on the basis of gross exami-
nation in tissue cultures and in animal models. Moreover, the 
unique three-atom linkage endows the inventive molecules 
with a certain rigidity not possessed in heteroarotinoids 
having a conventional two-carbon ester linker group. This 
structural feature is reasoned to be important in the interac-
tion of the molecules with nuclear receptors and is believed 
to contribute to decreased toxicity insofar as the body is well 
adept at processing urea derivatives. 
US 6,586,460 Bl 
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The heteroarotinoids of the present invention are very 
peripherally related in structure to trans-retinoic acid, 9-cis-
retinoic acid, and 13-cis-retinoic acid as illustrated. The 
inventive heteroarotinoids, shown in the general structures 1 
and 2, have either oxygen or sulfur as the heteroatom, two 
5 
aryl rings depending from the three atom linker (either urea 
or thiourea), and possess the indicated alternatives at G, R, 





















More particularly, the present invention encompasses 
heteroarotinoids of the following formulas, wherein G, R, Q, 
W and Z denote the indicated alternatives: 




R = H, CH3, OCH3 
Q=H,i-C3H7 
W=O,S 
Z = NOz, CO2Et, CO,-n-C4H9, SO2NH2 
lA z 
Isomeric heteroarotinoids having the formulas: 










Z = CO2H, CO2alkyl (CH3, C2Hs, n-C3H7, i-C3H7), NO2, SO2NH2 
60 
R = H, CH3, OCH3 
Q=H,i-C3H7 
W=O,S 
Z = NOz, CO2Et, CO,-n-C4H9, SO2NH2 
Heteroarotinoids with only one geminal group of the 
formulas: 





chemoprevention agent, an amount sufficient to exert a 
prophylactic effect or a preventative effect on recurrence 
after primary therapy, or a prevention of secondary tumors. 
In another aspect of the invention, the inventive mol-
ecules may also find use as a sensitizing agent administered 
in advance of or conconcurrently with a chemotherapeutic 





chemotherapeutic agent. In this respect an effective amount 
refers to amounts of the inventive heteroarotinoids capable 
of sensitizing tumor cells to treatment by one or more 
chemotherapy agents, including cisplatin, carboplatin, VP 
16, teniposide, daunorubicin, doxorubicin, dactinomycin, 
lA z 
G = H, CH3, C(O)-CH3 
R = H, CH3, OCH3 
W=O,S 
Z = NOz, CO2Et, CO,-n-C4H9 
15 mitomycin, plicamycin, bleomycin, procarbazine, 
nitrosourea, cyclophosphamide, bisulfan, melphalan, 
chlorambucil, ifosfamide, merchlorehtamine, taxol, 
taxotere, anthracyclines, and ionizing radiation. 
Biological data generated from a large number of repre-
sentative heteroarotinoids demonstrates significant inhibi- 20 
tion of growth of three ovarian cancer cell lines, namely, 
Caov-3, SKOV-3, and OVCAR-3 cell lines. In addition, the 
inventive heteroarotinoids were tested against three cell 
lines of the cervix, namely, SiHa, HT-3, and C-33A, and one 
vulvar cell line, SW962, using t-RA, 9-c-RA and 4-HPR as 25 
controls, wherein a range of inhibitory prowess was 
observed with several of the heteroarotinoids outperforming 
the standards. Representative agents screened for apoptosis 
effect were as good or better than 9-c-RA in inducing 
apoptosis ( cell death) of cancerous cells and were superior 30 
to 4-HPR, the clinically used agent. Xenograph investiga-
tions of representative heteroarotinoids using nude and 
immunocompromised mice injected with OVCAR-3 human 
carcinogenic cells were very demonstrative of the ability to 
reduce tumor volume and were comparable with that 35 
observed with 4-HPR. The concentrations used of the het-
eroarotinoids were in the microgram range. That the effect 
could be manifested at such a low concentration is sugges-
tive of a low toxicity in mammals. 
The heteroarotinoids according to the present invention 40 
hence find a use in therapy as antitumor agents, for the 
treatment or prophylaxis of benign, malignant, or metastatic 
neoplasms, as well as in the traditional indications for 
retinoids, such as skin disorders (acne, psoriasis), as well as 
degenerative disorders and/or inflammation of the mucosae. 45 
A better understanding of the present invention, its several 
aspects, and its advantages will become apparent to those 
skilled in the art from the following detailed description, 
taken in conjunction with the attached drawings, wherein 
there is shown and described the preferred embodiment of 
the invention, simply by way of illustration of the best mode 
contemplated for carrying out the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a comparative summary of average tumor 
volume over time as measured in mice in connection with in 
vivo tumor xenographs conducted to evaluate the inventive 
heteroarotinoids. 
FIG. 2 is a comparison of 1 µM doses of selected 
heteroarotinoids with 4-HPR in a cisplatin chemosensitiza-
tion study. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT 
Before explaining the present invention in detail, it is 
important to understand that the invention is not limited in 
its application to the details of the embodiments and steps 
described herein. The invention is capable of other embodi-
ments and of being practiced or carried out in a variety of 
ways. It is to be understood that the phraseology and 
terminology employed herein is for the purpose of descrip-
tion and not of limitation. 
Representative examples of the benzothiopyran deriva-
tives of formulas 1 and 2 and of the preferred reaction 
mechanisms used to obtain these compounds are illustrated 
in the reaction schemes below. As the first step, the synthesis 
of a few sulfur-containing members of 1 is outlined. Con-
The inventive heteroarotinoids may be readily provided in 
pharmaceutical compositions containing one or more of the 
heteroarotinoids, or of their addition salts with a pharma-
ceutically acceptable base or acid when a salifiable group is 
present, alone or in combination with one or more pharma- 50 
ceutically acceptable, non-toxic, inert vehicles or excipients. 
Among such pharmaceutical compositions, there may be 
mentioned, more especially, those which are suitable for 
oral, parenteral, nasal, rectal, perlingual, ocular or respira-
tory administration, and in particular, tablets, simple or 55 
sugar-coated, sublingual tablets, sachets, packs, hard gelatin 
capsules, preparations to be dissolved under the tongue, 
bars, suppositories, creams, ointments, skin gels, injectable 
preparations or preparations to be swallowed, aerosols, eye 
60 version of known structure 3 via nitration gave both the 
6-isomer 4 and the 8-isomer 5, which were separated by 
solvent extraction and purified by recrystallization. Purified 
4 and 5 were individually reduced to the corresponding 
or nose drops, and the like. 
The appropriate dosage will vary according to an indi-
vidual's age and weight, the administration route and the 
nature of the therapeutic indication and of any associated 
treatments, but will be an amount effective to exert a 
therapeutic effect on a tumor by any mechanism such as by 65 
killing tumor cells, reducing cell proliferation or reducing 
the size of the tumor or, in the case of its use as a 
amines 6 and 7, respectively, as in SCHEME I. In a similar 
reaction sequence, the 7-methyl derivative 8 was converted 
to the corresponding 6-nitro analog 9 which, in turn, was 












-5 to-8 pC 
5 
7 





















Treatment of 6 with a variety of isocycanates and/or 
isothiocyanates (W=O,S) led to compounds 11-16, all being 
substituted 6-isomers shown in SCHEME III. In a similar 
30 manner, treatment of 10 with isocyanates or isothiocyanates 
gave compounds 17-21. All members of 11-21 were puri-
fied and identified by spectroscopic techniques. Members of 
the 8-isomer family were prepared from 7 and gave 22-24 
which were purified and identified by spectroscopy and 
35 described in SCHEME IV. In addition, all products 11-24 
gave satisfactory elemental analyses, confirming the struc-
tures. 
SCHEME III 
R w z Number 
H s N02 11 
H s C02 Et 12 
H 0 C02 Et 13 
H 0 C02H 14 
H s S02NH2 15 
H s N02 16 
H 3 C s N02 17 
H 3 C s C02H 18 
H 3 C s N02 19 
H 3 C s S02NH2 20 
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SCHEME IV-continued 
G R w z Number 
5 H H s N02 22 
H H s C02 Et 23 
H H 0 C02 Et 24 
10 As representative members of 1 and 2, the syntheses of a 
15 
few examples, but not limited to those shown, of the 
oxygen-containing, isobenzopyran derivatives are delin-
eated in SCHEMES V and VI. Starting with known structure 
25, conversions to 25----;.26----;,27----;,28 (and 30 formed in same 
reaction)----;,29 gave the target compounds 31-36 (SCHEME 
V). Likewise, the 5-isomer 30 led to 37 which was converted 
to the final compounds 38-41 as shown in SCHEME VI. 
SCHEME V 
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SCHEME V-continued 
G w z Number 
H s NO2 31 
H s CO2 Et 32 
H 0 CO2 Et 33 
H 0 CO2 -n-Bu 34 
H3 C s NO2 35 








NH2 HNYW G 
37 '™'(\ I# 
z 
G w z Number 
H 0 CO2 Et 38 
H s CO2 Et 39 
H 0 COo-n-Bu 40 
H s NO2 41 
35 
Starting from 42----;,43, the conversion to 43----;,44 followed 
already described procedures. Heteroarotinoids 45 and 46 
were obtained from 44 via the addition to the latter of the 
isocyanate or isothiocyanate as illustrated in SCHEME VII. 
Elemental and spectral analyses confirmed the structures of 
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-continued 
As an additional test of the affect of an alkyl group on one 
of the nitrogen atoms, 6 was converted to the key interme-
diate 47 which in turn was utilized to generate 48 and 49 as 
illustrated in Scheme VIII. In a similar manner and as a 
representative example for the oxygen-containing systems, 
29 was converted to 50 and these to the target compound 51 
as is also shown in Scheme VII. Structures 48, 49, and 51 
were confirmed by both elemental and spectral analyses. 
46 
HNO3 (3.54 mL) and Ac2 O (9 mL) dropwise, and then the 
20 mixture was stirred (2 h). The new mixture was poured into 
a solution of saturated aqueous NaHCO3 , and the resulting 
mixture was extracted (H2 CC12 , 3x40 mL). After the organic 
solution was washed with water and brine, and, after drying 
(Na2 SO4), the solvent was evaporated to a solid which was 
25 recrystallized (hexane) to give 4 (1.6 g, 27%) as a white 




















The present invention will be further understood with 
reference to the following non-limiting experimental 
examples. 
EXAMPLE I 
2,2,4,4-Tetramethyl-6-nitrothiochroman (4) and 2,2, 
3,4-Tetramethyl-8-nitrothiochroman (5) 
To known thioether 3 (5.13 g, 24.86 mmol) in freshly 
distilled Ac2O (5 mL) at 0° C. was added a cold mixture of 
C(CH3 ) 2 ], 1.37 [s, 3 H, C(CH3 ) 2 ]. 1.52 [ps, 3 H, SC(CH3) 2 ], 
1.56 [s, 3 H, SC(CH3 ) 2 ], 2.03 [m, 3 H, CH2 ], 8.01 [d, 1 H, 
60 
Ar-H], 8.24 [ d, 2 H, Ar-H]; 13C NMR (DCC13 ) ppm 18.5 
[C(CH3) 2 ], 26.1 [C(CH3) 2 ], 32.0 [SC(CH3) 2 ], 34.5 [SC 
(CH3 ) 2 ], 34.75 [C(CH3) 2 , 46.3 [CH2 ], 54.4 [SC(CH3 )], and 
Ar-C [121.6, 121.8, 127.9, 128.3, 146.0, 146.5]. 
The filtrate from the recrystallization solvent (hexane) 
was concentrated and yielded 5 as a white solid, mp 65-67° 
65 C. 1H NMR (DCC13) ll 1.17 [s, 3 H, C(CH3 ) 2 ], 1.33 [s, 3 H, 
C(CH3 ) 2 ], 1.40 [s, 3 H, SC(CH3 ) 2 ], 1.46 [s, 3 H, SC(CH3) 2 ], 
2.16 [d, 2 H, CH2 ], 7.40 [m, 2 H, Ar-H], 7.79 [d, 1 H, 
US 6,586,460 Bl 
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Ar-H]; 13C NMR (DCCl3) ppm 19.6 [C(CH3)2], 25.1 
[C(CH3 ) 2 ], 32.6 [SC(CH3 ) 2 ], 34.4 [SC(CH3 ) 2 ], 34.6 
[C(CH3) 2 ], 45.2 [CH2 ], 52.4 [SC(CH3 ) 2 ], andAr-C [127.0, 
128.4, 130.8, 138.1, and 143.6]. 
16 
was added slowly. The aqueous layer was extracted (EtOAc, 
4x60 mL), and the combined organic extracts were washed 
with water and saturated NaHCO3. After the organic phase 
was dried (Na2SO4), the solvent was evaporated to an oil 
Both 4 and 5 were used in the conversions to 6 and 7 
without further purification. 
EXAMPLE II 
2,2,4,4-Tetramethyl-6-aminothiochroman ( 6) and 2, 
2,4,4-Tetramethyl-8-aminothiochroman (7) 
5 which was subjected to flash chromatography over silica gel 
(hexanes:EtOAc, 10:1). Fractions were collected which con-
tained 0.400 g ( 45%) of 10 as a dark yellow oil. The oil was 
used without further purification. 
It was found to be more efficient if the above mixture of 
Spectral data for 10: IR (neat) 3459 (N-H) cm-1; 1H 
10 NMR (DCC13) Ii 1.35 [s, 6 H, C(CH3)2], 1.37 [s, 6 H, 
OC(CH3)2], 1.89 [s, 2 H, CH2], 2.09 [s, 3 H, OCH3], 3.23 
[s, 2 H, NH2 ], 6.74 [s, 1 H, Ar-H], 7.83 [s, 1 H, Ar-H]. 
4 and 5 was reduced together to 6 and 7, which could be 
separated on silica gel. A mixture of 4 and 5 (3:2, 0.800 g, 
3.18 mmol) in acetic acid (29 mL) and water was stirred 15 
vigorously for a few moments. Then a solution of TiCl3/HCl 
(33.00 g, 21.39 mmol) was added dropwise, and the result-
ing mixture was stirred at room temperature for 2 h. The 
resulting reaction mixture was cooled (0° C.), and 30% 
aqueous NaOH (-130 mL) was added slowly. Extracts 20 
EtOAc (4x35 mL) and H2CC12 (2x40 mL) of the aqueous 
layer were combined, washed with water and saturated 
NaHCO3 and then dried (Na2SO4). Evaporation of the 
solvent and chromatography of the residual oil on silica gel 
(hexane:H2CC12, 1:1) gave 6 (0.211 g, 30%) as a white solid 
25 
(mp 45-50° C.) and 7 (0.140 g, 20%) as a solid (mp 61-63° 
C.). A second pass of the crude 6 through a fresh column 
gave a pure 6, mp of 57-59° C. 
Spectral data for 6: IR (KBr) 3450---3360 (N-H) cm-1; 
30 1H NMR (DCC13) Ii 1.36 [s, 6 H, C(CH3)2], 1.39 [s, 6 H, 
SC(CH3)2], 1.90 [s, 2 H, CH2], 3.50 [bs, 2 H, NH2], 6.44 [d, 
1 H,Ar-H], 6.75 [s, 1 H,Ar-H], 9.92 [d, 1 H,Ar-H]; 13C 
NMR (DCC13) ppm 31.6 [C(CH3)2], 32.0 [SC(CH3)2], 35.7 
[C(CH3)2], 41.8 [SC(CH3)2], 54.7 [CH2], andAr-C [113.7, 35 
113.8, 121.2, 129.1, 143.9, and 144.1]. 
Spectral data for 7: IR (KBr) 3460---3372 (N-H) cm-1; 
1H NMR (DCC13) Ii 1.39 [s, 6 H, C(CH3)2], 1.42 [s, 6 H, 
SC(CH3)2], 1.91 [s, 2 H, CH2], 3.89 [bs, 2 H, NH2]. 6/.56 [d, 
1 H,Ar-H], 6.91 [m, 2 H,Ar-H]; 13C NMR (DCC13) ppm 40 
31.8 [C(CH3)2], 31.9 [SC(CH3)2], 36.0 [C(CH3)2], 42.2 
[SC(CH3)2], 54.4 [CH2], and Ar-C [112.3, 116.6, 117.7, 
125.0, 143.5, and 144.4]. 
EXAMPLE IV 
[N-( 4-Nitrophenyl)amino ][2,2,4,4-tetramethyl { 3H-
benzo[3,4-e ]thiany-6-yl} )amino ]methane-1-thione 
(11) and Analogs Thereof (12-21) 
To a solution of 6 (0.200 g, 0.9 mmol) in THF (4 mL) at 
0° C. was added dropwise 4-nitrophenylisocyanate (170 mg, 
0.9 mmol) in THF (5 mL) under N2. When the addition was 
complete, the mixture was stirred overnight. Evaporation of 
the solvent gave a solid which was recrystallized (pentane: 
HCC13; 1:1) to yield a very light yellow solid 11, mp 
153-155° C. 1H NMR (DCC13) Ii 1.39 [s, 6 H, C(CH3)2], 
1.44 [s, 6 H, SC(CH3)2], 1.97 [s, 2H, CH2], 7.18 [d, 2 H, 
Ar-H], 7.23 [d, 1 H,Ar-H], 7.34 [d, 1 H,Ar-H], 7.24 [d, 
2 H,Ar-H]], 7.96 [bs, 1 H]], 8.20 [d, 2 H,Ar-H], 8.44 [bs, 
1 H]; 13C NMR (DCCl3) ppm 31.4, 32.3, 35.7, 42.3, 53.5, 
and Ar-C [122.9, 123.0, 124.1, 124.6, 129.5, 132.2, 133.9, 
143.9, 144.5, and 145.1], and 179.0 (C=O). Anal. Calcd for 
C20H23N3O2S2: C, 59.82; H, 5.77; 10.46; S, 15.97. Found: 
C, 59.79; H, 5.79; N, 10.54; S, 15.87. 
Other examples including members of 12-16 were pre-
pared in an identical fashion from 6 while 17-21 were 
obtained from 10 in a like manner. The products 12-21 gave 
the following physical data. 
12: mp 134--135° C.; 1 H NMR (DCC13) Ii 1.38 [ s, 6 H], 
1.40 [t, 2 H], 1.43 [s, 6 H], 1.95 [s, 2 H], 4.35[q, 2 H], 7.04 
[dd, 1 H], 7.16 [d, 1 H,Ar-H], 7.36 [d, 1 H,Ar-H], 7.55 
[d, 2 H, Ar-H], 8.00 [s, 1 H, NH], 8.02 [d, 2 H, Ar-H], 
8.35 [s, 1 H, NH]; 13C NMR (DCC13) ppm 31.4, 32.2, 35.6, 
42.0, 54.1, 60.9, and Ar-C [118.4, 120.0, 120.6, 124.8, 
EXAMPLE III 
6-Nitro-2,2,4,4,7-pentamethylthiochroman (9) and 
6-Amino-2,2,4,4,7-pentamethylthiochroman (10) 
45 
130.9, 134.4, 142.9, and 144.2], and 153.3 (C=O) and 
166.7 (C=O). Calcd for C23H28N2O2S2: C, 64.45; H, 6.58; 
N, 6.53; S, 14.96. Found: C, 64.57; H, 6.66; N, 6.57; S, 
14.86. 
Thia ether 8 (22.00 g, 99.83 mmol) inAc2O (23 mL) was 
treated dropwise with cold, concentrated HN03 (23 mL) at 50 
-5° C., and then the mixture was stirred (1 h). The resulting 
mixture was poured into a solution of saturated NaHCO3, 
and the newly formed mixture was extracted (H2CC12, 
3x200 mL). After the extracts were washed with water and 
brine, the organic layer was dried (Na2SO4) and then evapo- 55 
rated to an oil which was distilled (bp 160-162° C.) to a 
thick oil (7 g, 26%). The oil 9 was used immediately to 
prepare 10 without further purification. 
Spectral data for 9: 1H NMR (DCC13) Ii 1.11 [s, 3 H, 
CH3], 1.33 [s, 3 H, CH3], 1.50 [s, 3 H, OCCH3], 1.51 [s, 3 60 
H, CH3], 2.03 [s, 2 H, CH2], 2.64 [s. 3 H, OCH3], 2.64 [s, 
3 H, OCH3], 7.78 [s, 1 H, Ar-H], 7.97 [s, 1 H, Ar-H]. 
Ether 9 (1.0 g, 3.77 mmol) in AcOH ((36 mL) and water 
(7 mL) was stirred vigorously, and then TiCl3/HCl ( 40.07 g, 
26.38 mmol) was added dropwise. The resulting mixture 65 
was stirred at room temperature for 7 h. The new mixture 
was cooled (0° C.), and a 30% aqueous solution of NaOH 
13: mp 200-201 ° C.; 1H NMR (DCC13) ll 1.32, 1.35, 1.37, 
1.40, 1.89, 4.35, 6.9-7.56 (m), 7.91. Calcd for 
C23H28N2O3S: C, 66.96; H, 6.84; N, 6.79; S, 7.77. Found: 
C, 67.04; H, 6.86; N, 6.83; S, 7.83. 
14: mp 293° C. (dee); IR (KBr) 3359 (O-H), 1696 
(C=O) cm-1; 1H NMR DMSO-d6) Ii 1.89, 3.34, 6.96 [d], 
7.17 [dd], 7.56 [m], 7.85 [d], 8.70 [s], and 8.99 [s]; 13C NMR 
(DMSO-d6) ppm 31.2, 32.2, 35.3, 53.7, and Ar-C [117.2, 
117.33, 117.38, 123.6, 125.0, 128.0, 130.7, 136.9, 143.1, 
144.2], and 152.4 [C=O], and 167.2 [C=O]. Calcd for 
C21H24N2O3S: C, 65.60; H, 6.29; N, 7.29; S, 8.34. Found: 
C, 65.60; H, 6.28; n, 7.25; S, 8.34. 
15: mp 191-193° C.; IR (KBr) 3358, 3272 (N-H) cm-1; 
1H NMR (DMSO-d6) Ii 1.32, 1.37, 1.91, 7.01, 7.24, 7.60, 
9.98; 13C NMR (DMSO-d6) ppm 31.2, 32.2, 35.2, 42.0, 
53.4, and Ar-C [122.0, 126.3, 127.4, 128.1, 136.4, 139.1, 
142.6] and 179.4 (C=O). Calcd for C20H25N3O2S3; C, 
55.14,; H, 5.79; N, 9.65; S, 22.08. Found: C, 55.15; H, 5.82; 
N, 9.62; S, 22.12. 
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16: mp 155-156° C.; IR (KBr) 3344, 3120 (N-H) cm-1 ; 
1H NMR (DCC13 ) Ii 1.40, 1.43, 1.97, 2.25, 7.06, 7.24, 7.37, 
7.42, 8.06; 13C NMR (DCC13 ) ppm 17.9, 31.4, 32.3, 35.7, 
42.4, 53.6, and Ar-C [122.1, 123.7, 124.8, 125.8, 126.4, 
129.6, 132.3, 133.5, 134.4, 142.4, 145.3, 145.4], and 179.9 5 
(C=O). Calcd for C21H25N3 O2 S2 : C, 60.60; H, 6.06; N, 
10.11; S, 15.43. Found: C, 60.41; H, 6.01; N, 9.93; S, 15.51. 
17: mp 172-173° C.; IR (KBr) 3345, 3160 (N-H) cm-1 ; 
1H NMR (DCC13 ) ll 1.38, 1.44, 1.96, 2.52, 7.10, 7.30, 7.60, 
7.75, 8.00; 13C NMR (DCC13 ) ppm 17.1, 31.5, 32.7, 35.4, 10 
42.4, 53.6, and Ar-C [123.0, 12.4, 125.9, 130.5, 136.6, 
133.2, 134.9, 142.5, 143.9, 144.5] and 179.5. Calcd for 
C21H25N3 O2S2 : C, 60.69; H, 6.06; N, 10.11; S, 15.43. 
Found: C, 60.77; H, 6.09; N, 10.02; S, 15.53. 
18: mp 266° C. (dee); IR (KBr) 3366, 3167 (N-H) cm-1; 15 
1H NMR (DMSO-d6) Ii 1.31, 1.37, 1.90, 2.16, 6.93, 7.34, 
7.30, 7.65, 7.66, 7.87, 9.52, 9.97. 13C NMR (DMSO-d6) 
ppm 17.1, 31.2, 32.4, 34.8, 38.6, 41.9, 534, and Ar-C 
[121.8, 121.9, 125.6, 126.3, 128.6, 129.7, 132.5, 134.6, 
139.9, 143.8], and 166.9, 180.0 (C=O). C22H26N2 O2S2 : C, 
20 
63.73; H, 6.32; N, 6.76; S, 15.47. Found: C, 63.77; H, 6.21; 
N, 6.76; S, 15.60. 
19: mp 174--175° C.; IR (KBr) 3302, 3174 (N-H) cm-1; 
1H NMR (DCC13 ) ll 1.38, 1.43, 1.96, 2.16, 2.82, 7.11, 7.35, 
8.06, 8.10, 8.25; 13C NMR (DCC13) ppm 17.1, 17.8, 31.5, 
25 
32.6, 35.4, 42.4, 53.7, and Ar-C [121.9, 125.7, 126.3, 
126.4, 130.6, 133.3, 133.7, 135.2, 142.3, 142.5, 145.3] and 
179.8. Calcd for C22H27N3 O2 S2 : C, 61.51; H, 6.33; N, 9.78; 
S, 14.93. Found C, 61.49; H, 6.26; N, 9.63; S, 14.95. 
30 
20: mp 190---192° C.; IR (KBr) 3366, 3267 (N-H) cm-1; 
1H NMR (DCC13 ) ll 1.31, 1.37, 1.91, 2.16, 6.94, 7.30, 7.35, 
7.36, 7.76, 9.53, 9.92; 13C NMR (DCC13 ) ppm 17.1, 31.2, 
32.4, 34.8, 41.9, 53.4, and Ar-C [122.6, 122.7, 126.0, 
126.3, 128.6, 129.8, 132.5, 134.5, 139.9, 142.7] and 180.2. 
35 
Calcd for C21H27N3 O2S3 : C, 56.09; H, 6.05; N, 9.34; S, 
21.39. Found: C, 56.14; H, 6.06; N, 9.28; S, 21.45. 
21: mp 128-129° C.; IR (KBr) 3310, 3203 (N-H), 1716 
(C=O) cm-1; ll1 H NMR (DCC13) ll 1.34, 1.38, 1.89, 2.12, 
4.33, 6.86, 6.95, 7.32, 7.49, 7.53, 7.89. 13C NMR (DDC13 ) 40 
ppm 14.3, 17.1, 31.5, 32.5, 35.3, 42.1, 54.0, 60.8, andAr-C 
[118.2, 124.0, 124.6, 129.9, 130.4, 130.7, 132.0, 141.6, 
142.8, 154.8], and 166.4, 179.6. Calcd for C24H30N2 O2S: C, 
67.58; H, 7.09; N, 6.57; S, 7.52. Found: C, 67.66; H, 7.21; 
18 
4-iosthiocyanatobenzoate, respectively. Esters 23 and 24 
gave the following physical data. 
23: mp 143-144° C.; IR (KBr) 1712 cm-1; 1H NMR 
(DCC13) ll 1.38, 1.40, 1.41, 1.96, 4.36 7.16, 7.36, 7.56, 7.79, 
7.88, 8.02; 13C NMR (DCC13 ) ppm 31.4, 32.5, 35.8, 42.3, 
53.7, 60.9, and Ar-C [123.4, 124.5, 124.9, 126.4, 127.6, 
1'30.6, 131.3, 133.0, 141.9, 145.2] and 166.0, 179.6. Calcd 
for C23H28N2 O2S2 : C, 64.45; H, 6.58; N, 6.54; S, 14.96. 
Found: C, 64.41; H, 6.57; N, 6.54; S, 14.98. 
24: mp 155-156° C.; IR (KBr) 3387, 3258, (N-H), 1715 
(C=O), 1672 (C=O) cm-1; 1H NMR (DCC13 ) ll 1.26, 1.34, 
1.36, 1.85, 4.34, 7.05, 7.19, 7.24, 7.47, 7.89, 8.03; 13C NMR 
(DCC13) ppm 14.1, 31.5, 32.2, 35.9, 42.4, 53.8, 60.7, and 
Ar-C[118.3, 121.8, 123.4, 124.2, 124.9, 126.9, 130.8, 
134.0, 144.4] and 153.5, 166.8. Calcd for C23H28N2 O3 S: C, 
66.96; H, 6./84; N, 6.79; S, 7.77. Found: C, 67.01; H, 6.83; 
N, 6.79; S, 7.77. Base (NaOH/95% ethanol) catalyzed 
hydrolysis of 24 by standard conditions gave the corre-
sponding acid derivative which was analyzed, mp 308° C. 
(dee); IR (KBr) 3310-2600 [C(O)-O-H], 1692 (C=O) 
cm-1 ; 1H NMR (DMSO-d6) Ii 1.35, 1.38, 1.91, 7.07, 7.24, 
7.55, 7.86, 9.60; 13C NMR (DMSO-d6) ppm 31.3, 32.2, 
35.6, 42.2, 53.4, and Ar-C [117.1, 120.5, 122.2, 123.6, 
124.2, 124.6, 130.7, 134.9, 143.6, 144.3], and 152.5, 167.2. 
Calcd for C21H24N2 O3 S: C, 65.60; H, 6.29; N, 7.29; S, 8.34. 






dihydro- lH-2-benzopyran (29), and 1,1,4,4-
Tetramethy 1-6-methoxy-5-amino-3,4-dihydro-lH-2-
benzopyran (37) 
Treatment of 27 (18.0 g, 81.7 mmol), prepared from the 
reaction sequence 25----;.26 as found in the recent literature 
[Journal of Medicinal Chemistry, 1999, Vol. 42, pages 
4434-4445, and the article is entitled "Heteroarotinoids 
Inhibit Head and Neck Cancer Cell Lines in vitro and in vivo 
Through Both RAR and RXR Retinoic Acid Receptors" by 
D. Zacheis, A Dhar, S. Lu, M. M. Madler, J. Klucik, C. W. 
N, 6.54; S, 7.44. 45 Brown, S. Liu, F. Clement, S. Subramanian, G. M. 
EXAMPLE V 
[ ( 4-Nitrophenyl)amino ][ (2,2,4,4-tetramethyl { 3H-
benzo[3,4-e ]thiany-8-yl} )amino ]methane-1-thione 
(22) and Analogs Thereof (23 and 24) 
Treatment of slightly crude amine 7 (0.200 g, 0.90 mmol) 
in THF (5 mL) was treated dropwise with 
4-nitrophenylisothiocyanate (0.63 g, 0.90 mmol) in THF at 
0-5° C. under N2 . The mixture was allowed to warm to room 
temperature and then was stirred overnight. Removal of the 
solvent gave a solid which was recrystallized (ether) and 
gave pure 22 (0.110 g, 30%), mp 137° C. (dee); IR (KBr) 
3100 (N-H) cm-1; 1H NMR (DCC13 ) Ii 1.39, 1.40, 1.96, 
7.18, 7.43, 7.71, 7.96, 8.17; 13C NMR (DCC13 ) ppm 31.4, 
32.7, 35.8, 42.5, 53.6, and Ar-C [120.4, 123.3, 124.6, 
125.1, 125.2, 127.2, 132.1, 143.9, 144.7, 145.7] and 178.9. 
Calcd for C20H23N3 O2S2 : C, 59.82; H, 5.77; N, 10.47; S, 
15.97. Calcd for C20H23N3 O2 S2 0.25 H2 O : C, 59.16; H, 
5.71; N, 10.35; S, 15.79. Found: C, 59.17; H, 5.76; N, 10.31; 
s, 15.82. 
In a similar manner, 23 and 24 were prepared from 7 and 
ethyl 4-isocyanantobenzoate and ethyl 
Weerasekare, K. D. Berlin, M.A. Gold, J. R. Houch, Jr., K. 
R. Fountain, and D. M. Benbrook.], dropwise with a mixture 
of cold, concentrated HNO3 (18 mL and Ac2 O (36 ml) at -5 
to -8° C. gave a solution which was stirred for 1 h. The 
50 mixture was poured into a saturated aqueous solution of 
aqueous NaHCO3 (300 mL), and the resulting mixture was 
extracted (H2 CC12 ). After separation, the aqueous layer was 
washed with water and brine and then dried (Na2 SO4). 
Evaporation of the solvent gave an oil which was triturated 
55 with pentane to yield a solid that was recrystallized (95% 
ethanol) to give 28 (13.49 g, 63%), mp 124--125° C. 1H 
NMR (DCC13) ll 1.28, 1.51, 3.58, 3.94, 6.94, 7.59; 
13C NMR 
(DCC13) ppm 26.6, 29.5, 34.5, 56.4, 70.1, 74.6, and Ar-C 
[110.2, 122.1, 134.5, 137.7, 150.2, 151.5]. MS (EI) calcd for 
60 C14H 19N04 (M+): 265. Found: 265. 
Additional chromatography on silica gel (hexane:ether, 
9:1) of the filtrate gave a solid which was recrystallized 
(95% ethanol) to yield 30 (6.91 g, 32%), mp 82-83° C. 1H 
NMR (DCC13) ll 1.28, 1.51, 3.48, 3.83, 6.88, 7.12; 
13C NMR 
65 (DCC13) ppm 24.0, 30.0, 34.1, 56.3, 71.6, 74.1, and Ar-C 
[110.6, 128.1, 134.5, 135.5, 140.8, 159.3; MS (EI) calcd for 
C14H19NQ4 (M+): 265. Found: 265. Compounds 28 and 30 
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were used immediately without further purification to pre-
pare 29 and 37, respectively. 
To 28 (7.0 g, 26.38 mmol) in AcOH (250 mL) and water 
(5 mL) vigorously stirred was added dropwise TiCl3/HCl 
(400.g, 259.3 mmol) which was followed by stirring for 7 h 5 
at room temperature. The resulting mixture was cooled (0° 
C.), and 30% aqueous NaOH was added (1 L). Separation 
and extraction (EeOAc, 8x200 mL) gave an organic layer 
which was washed with water and saturated aqueous 
NaHCO3 and then was dried (Na2SO4). Evaporation of the 10 
solvent gave a solid which was recrystallized (95% ethanol) 
to give 29 (5.05 g, 81%), mp 126-127° C.; IR (Kbr) 3449, 
3188 (N-H); 1H NMR (DCC13) Ii 1.24, 1.48, 3.56, 3.64, 
3.85, 6.41, 7.67; 13C NMR (DCC13) ppm 27.0, 29.7, 33.4, 
55.4, 71.1, 74.8, and Ar-C [106.7, 111.7, 132.7, 134.0, 
15 
146.2]. MS (EI) calcd for C14H19NO4 (M+): 235. Found: 
235. 
To 30 (5.7 g, 17.7 mmol) in AcOH (206 mL) and water 
20 
7.83 [s, 1 H, Ar-H(8)], 7.97 [d, 1=8.8 Hz, Ar-H(14), 
Ar-H(16)]; 13C NMR (DCCl3) ppm 14.32, [C(CH3)2], 
26.98 [OC(CH3)2], 29.68 [CH3], 33.82 [C(CH3)2], 55.68 
[SC(CH3)2], 60.88 [CH2], 70.78 [CH2], 75.23 [OCH3], and 
Ar-C [106.6, 117.0, 118.2, 124.6, 125.5, 130.8, 134.3, 
137.6, 143.0, 147.0], 152.31 [NHCONH], and 166.54 
[C=O]. Calcd for C24H30N2O5: C, 67.58; H 7.09; N, 6.57. 
Found: C, 67.47; H, 7.16; N, 6.49. 
34: mp 148-149° C. IR (KBr) 3423, 3310 (N-H), 1716 
(C=O), cm-1; 1H NMR (DCC13) Ii 1.01, 1.29, 1.47, 1.53, 
1.15, 3.62, 3.84, 4.35, 6.78, 7.38, 7.49, 7.53, 7.87, 8.02; 13C 
NMR (DCC13) ppm 13.6, 19.2, 26.9, 29.6, 29.6, 33.8, 55.6, 
64.7, 70.7, 75.2, and Ar-C [106.6, 117.1, 118.3, 124.7, 
125.5, 130.9, 134.4, 137.8, 143.1, 147.1], 152.3 
[NHCONH], and 166.7 [C=O]. Calcd for C26H34N2O5: C, 
68.70; H, 7.54; N, 6.16. Found: C, 68.55; H, 7.50; N, 6.10. 
( 42 mL) with vigorous stirring was added dropwise TiCl3/ 
HCl (30%, 120 g, 177.1 mmol). After stiring at room 
temperature for 13 h, the mixture was cooled (0° C.), and 
30% aqueous NaOH (500 mL) was added cautiously. The 
combined extracts (EtOAc, 8x100 mL) of the aqueous layer 
were washed with water and a saturated aqueous solution of 
NaHCO3 and then was dried (Na2SO4). Evaporation of the 
solvent gave a solid which was recrystallized (95% ethanol) 
to give pure 37 (3.0 g, 58%), mp 110---112° C.; IR (KBr) 
3449, 3338 (N-H); 1H NMR (DCC13) Ii 1.37, 1.49, 3.53, 
3.83, 3.98, 6.50, 7.69; 13C NMR (DCC13) ppm 27.0, 29.7, 
33.4, 55.4, 71.7, 74.8, and Ar-C [106.7, 111.7, 132.7, 
134.0, 146.2]. MS (EI) calcd for C14H19NO4 (M+): 235. 
Found: 235. 
35: mp 176-177° C. IR (KBr) 3224, 3125 (N-H), cm-1; 
1H NMR (DCC13) ll 1.31, 1.55, 2.39, 3.63, 3.89, 6.84, 7.60, 
7.74, 7.87, 8.07-8.12; 13C NMR (DCC13) ppm 18.0, 26.8, 
29.7, 34.1, 55.9, 70.5, 74.8, andAr-C [108.0, 122.1, 122.4, 
20 123.3, 126.0, 126.1, 133.9, 134.7, 142.0, 142.9, 145.4, 
150.5], and 179.3 [C=S]. Calcd for C22H27N3Q4S: C, 
61.52; H, 6.34; N, 9.78; S, 7.46. Found: C, 61.64; H, 6.34; 
N, 9.72; S, 7.46. 
36: mp 198-199° C. IR (KBr) 3311 (broad, N-H) cm-1; 
25 1H NMR (DCC13) ll 1.23, 1.42, 3.50, 3.84, 6.95, 7.29, 7.67, 
7.77, 9.33, 10.19; 13C NMR (DMSO-d6) ppm 26.5, 29.5, 
33.6, 55.7, 69.9, 74.3, and Ar-C [107.7, 122.4, 122.9, 
125.1, 126.0, 132.7, 139.0, 140.0, 142.5, 150.3], and 179.17 
[C=S]. Calcd for C21H27N3O4S2: C, 56.10; H, 6.05; N, 
30 9.35; S, 14.26. Found: C, 55.95; H, 6.02; N, 9.22; S, 14.21. 
EXAMPLE VII 
[( 6-Methoxy-1,1,4,4-tetramethylisochroman-7-yl) 
amino][( 4-nitrophenyl)amino ]methane 1-Thione 
(31) and Analogs Thereof (32-36) 
A solution of 29 (0.200 g, 0.85 mmol) in THF ( 4 mL) was 
treated dropwise with a solution of 
35 
4-nitrophenylisothiocyanate (0.169 g, 0.94 mmol) in THF (5 40 
mL) at 0° C. under N2. After the mixture had warmed to 
room temperature, it was stirred overnight. Evaporation of 
the solvent gave an oil which crystallized and then was 
recrystallized (pentane:H2CC12, 3:1) to yield 31 as a light 
yellow solid (0.300 g, 83% ), mp 178-179° C. IR 3373, 3300 45 
(N-H); 1H NMR (DCC13) Ii 1.29, 1.51, 3.60, 3.89, 6.88, 
7.27, 7.44, 7.68, 8.02, 8.24; 13C NMR (DCC13) ppm 26.8, 
29.7,34.1, 55.9, 70.5, 74.8, andAr-C [108.4, 122.0, 122.4, 
123.2, 124.9, 135.0, 143.1, 143.8, 144.5, 150.4], and 178.7 
(C=S). Calcd for C21H25N3O4S: C, 60.70; H, 6.07; N, 
10.11; S, 7.72. Found: C, 60.42; H, 5.98; N, 10.10; S, 7.65. 50 
In a similar manner, 32-36 were prepared from 29 and the 
required substituted isothio- or isocycanate. Compounds 




amino }benzoate (38) 
Amine 37 (200 mg, 0.85 mmol) was dissolved with 5 mL 
of dry THF in dried equipment and was then cooled to -5° 
C. Ethyl 4-isocyanatobenzoate (170.6 mg, 8.92 mmol, 1.05 
eq) dissolved in 5 mL of dry THF was added dropwise. After 
addition, the reaction mixture was allowed to warm to RT 
and was stirred for 24 h. Evaporation of the solvent gave a 
solid which was recrystallized (H2CC12:pentane, 2:1) to 
afford 38 (mp 147-9° C., 265 mg, 73%) as a white solid. IR 
(KBr) 3442, 3432(N-H), 1732(C=O) cm-1; 1H NMR 
(DCC13) ll 1.23 [t, 3 H, OCH2CH3], 1.26 [s, 6 H, C(CH3)2], 
1.36 [ s, 6 H, C(CH3)2], 3.17 [ s, 2 H, OCH2], 3.85 [ s, 3 H, 
Ar-OCH3], 4.23 [q, 2 H, -ocH2], 6.90 [d, 1 H, 1=7.3 Hz, 
Ar-H], 7.15 [d, 1 H, 1=7.3 Hz, Ar-H], 7.23 [bs, 1 H, 
N-H], 7.58 [d, 1 H, 1=7.6 Hz, Ar-H], 7.84 [d, 1 H, 1=7.6 
Hz, Ar-H], 9.18 [bs, 1 H, N-H]; 13C NMR (DCC13) ppm 
25.9 [C(CH3)2], 28.6 [C(CH3)2], 34.9 [OCH2CH3], 51.4 
[C(CH3)], 54.8 [C(CH3)], 71.7 [(CH3)2OCH2], 105.2 [Ar-
OCH3], 116.8-146.7 [Ar-C], 163.4 [C=O], and 166.47 
[C=O]; Calcd. for C25H30N2O5: C, 67.58; H, 7.08; N, 6.56. 
55 Found: C, 67.50; H, 7.10; N, 6.48. 
32: mp 166-168° C. IR (KBr) 3351, 3171 (N-H), 1715 
(C=O) cm-1; 1H NMR (DCC13) Ii 1.27, 1.39, 1.52, 3.59, 
3.83, 4.38, 6.81, 7.49, 7.78, 8.06, 8.25; 13C NMR (DCC13) 
ppm 14.1, 26.7, 29.6, 33.9, 55.8, 61.0, 70.6, 74.9, andAr-C 
[107.6, 121.5, 122.7, 124.12, 127.73, 131.03, 134.33, 
141.50, 141.71, 149.80], 165.91 (C=O), and 178.42 
(C=S). Calcd for C21H25N3O4S: C, 65.13; H, 6.83; N, 6.33; 60 
S, 7.25. Found: C, 64.93; H, 6.82; N, 6.29; S,7.20. 
33: mp 142-144° C. IR (KBr) 3351, 3171(N-H), 1715 
(C=O) cm-1; 1H NMR (DCC13) ll 1.25 [s, 6 H, CC(CH3)2], 
1.38 [t, 3 H, 1=7.1 Hz, CH3], 1.53 [s, 6 H, OC(CH3)2], 3.58 
[s, 2 H, CH2], 3.80 [s, 3 H, OCH3], 4.36 [q, 2 H, 1=7.0 Hz, 65 
CH2), 6.74 [s, 1 H,Ar-H(5)], 7.36 [s, 1 H, N(9)H], 7.48 [d, 
2 H, 1=9.l, Ar-H(13), Ar-H(l 7)], 7.50 [s, 1 H, N(ll)H], 
In a similar manner, 39-41 were prepared from 37 and the 
required substituted isothio- or isocycanate. Compounds 
39-41 gave the following physical data. 
39: mp 166-167° C. 1H NMR(DCC13) ll 1.34, 1.37, 1.39, 
1.53, 1.74, 1.83, 3.52, 3.85, 4.34, 6.91, 7.17, 7.28, 7.53, 
7.99; 13C NMR (DCC13) ppm 14.1, 24.7, 29.8, 34.1, 56.0, 
60.8, 72.0, 110.3, 114.0, 121.6, 123.7, 127.5, 128.0, 130.2, 
136.5, 142.6, 154.2, 166.0, 180.7. Calcd for C24H30N3Q4S: 
C, 65.13; H, 6.83; N, 6.33; S, 7.24. Found: C, 65.14; H, 6.88; 
N, 6.48; S, 7.19. 
40: mp 196-198° C. 1H NMR (DCC13) Ii 0.95-1.38 (m), 
1.41-1.55 (m), 1.66-181 (m), 3.33, 3.76, 4.22, 6.76, 6.79, 
US 6,586,460 Bl 
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OCH2 ], 4.34 [q, 2 H, 1=7.1 Hz, OCH2 CH3], 7.50 [d, 2 H, 
1=8.8 Hz, Ar-H], 7.66 [d, 1 H, 1=2 H, 1=2.0 Hz, Ar-H], 
7.80 [s, 1 H, NH], 7.94 [d, 2 H, 1=2.0 Hz, Ar-H], 8.36 [s, 
1 H, NH], 8.65 [s, 1 H, 1=2.0 Hz, Ar-H]; 13C NMR 
6.97, 7.00, 7.27, 7.56; 13C NMR (DCC13) ppm 13.6, 16.1, 
24.9, 30.6, 33.9, 34.4, 55.8, 55.9, 64.4, 72.1, 75./0, 75.9, 
109.7, 117.7, 118.0, 122.9, 123.1, 130.5, 135.5, 142.2, 
143.1, 154.9, 155.5, 166.1. Calcd for C26H24N2 O5 : C, 68.70; 
H, 7.54; N, 6.15. Found: C, 68.81; H, 7.60; N, 6.07. 
41: mp 181-182° C. IR (KBr) 3226, 3132 (N-H) cm-1 , 
5 (DCC13) ppm 14.20, 26.44, 30.49, 36.68, 60.90, 63.86, and 
Ar-C [118.13, 121.31, 124.38, 127.25, 129.54, 130.93, 
131.36, 143.47, 146.79, 152.67], 166.89, and 198.75 
[C=O]. Calcd for C23H26N2 O5 : C, 67.30; H, 6.38; N, 6.82. 
1H NMR (DCC13) Ii 1.28, 1.48, 3.58, 3.83, 6.84, 7.25, 7.60, 
7.81, 8.15, 8.18; 13C NMR (DCC13) ppm 26.8, 29.7, 55.4, 
70.5, 74.8, 108.6, 122.1-150.5, 169.4. Calcd. for 
C21H25O4 N3S: C, 60.70; H, 6.06; N, 10.11; S, 7.71. Found: 10 
C, 60.63; H, 6.01; N, 10.11; S, 7.69. 
EXAMPLE IX 
Found: C, 67.24; H, 6.49; N, 6.86. 
To a solution of amine 44 (0.300 g, 1.31 mmol) in THF 
(6 mL) was added dropwise 4-nitrophenylisothiocyanate 
(0.210 g, 1.50 mmol) in THF (6 mL) at -5° C. under N2 . The 
reaction mixture was allowed to warm to room temperature 
and was stirred overnight. Evaporation of the solvent Ethyl 4-{[N-( 6-Acetyl-4,4-dimethylchroman-8-yl) 
carbamoyl]amino }benzoate ( 45) and N-[(6-Acetyl-
4,4-dimethylchroman-8-yl)]( 4-nitrophenyl)amino] 
carboxamide ( 46) 
To 4,4-dimethylchroman-6-yl methyl ketone (42, 5.5 g, 
26.93 mmol) dissolved inAc2 O (12 mL) at-8° C. was added 
dropwise a mixture of cold, concentrated HN03 (6 mL) and 
Ac2O (12 mL) over 10 min after which time the mixture was 
stirred (1 h). The resulting mixture was then poured into a 
solution of saturated aqueous NaHCO3 (100 mL), and the 
resulting mixture was extracted (H2 CC12 , 3x40 mL). The 
organic layer was washed with water (50 mL) and brine (50 
mL) and was then dried (Na2SO4). The solvent was evapo-
rated to a thick yellow oil which was triturated with pentane 
15 afforded a yellow oil. Recrystallization [95% EtOH] gave 46 
(0.500 g, 91 %) as a light yellow solid, mp 123° C. (dee). IR 
(KBr) 3383, 3110 (N-H), 1680 (C=O) cm-1; 1H NMR 
(DCC13) ll 1.35 [s, 6 H, C(CH3)2 ], 1.90 [t, 2 H, 1=5.0, CH2 ], 
2.56 [s, 3 H, C(O)CH3], 3.34 [t, 2 H. 1=5.3, CH2 ], 4.62 [s, 
20 1 H, NH], 7.83 [s, 1 H, Ar-H], 7.95 [m, 2 H, Ar-H], 8.19 
[m, 2 H, Ar-H], 8.33 [s, 1 H, NH], 8.47 [s, 1 H, Ar-H], 
8.66 [s, 1 H, Ar-H]. 13C NMR (DCC13) ppm 26.28 [CH2 ], 
30.44 [CH3], 30.67 [CH3], 36.42 [OCH2 ], 50.70 [C(CH3)2 ], 
64.27 [COCH3], and Ar-C [122.47, 122.74, 125.00, 
25 125.09, 125.41, 129.28, 132.73, 143.77, 144.46, 149.86], 
178.68 [C=S], and 197.16 [C=O]. Calcd for 
C20H21N3Q4S: C, 60.13; H, 5.30; N, 10.52; S, 8.03. Calcd 
for C20H21N3O4S.0.5 H2 O: C, 58.81; H, 5.43; N, 10.29; S, to give a light yellow solid (5 g, 75%). Recrystallization 
(CH 2 Cl2 :pentane 3:1) gave pure 43 (8-nitro-4,4- 30 
dimethylchroman-6-yl)methyl ketone (4.14 g, 62%) as a 
light yellow solid, mp 117-119° C. IR (KBr) 1360 (NO2) 
cm-1 ; 1H NMR (DCC13) ll 1.41 [s, 6 H, C(CH3)2 ], 1.95 [s, 
2 H, CCH2 ], 2.59 [s, 3 H, COCH3], 4.42 [t, 2 H, OCH2 ], 8.15 
[d, 1 H, Ar-H], 8.20 [d, 1 H, Ar-H]; 13C NMR (DCC13) 35 
ppm 26.1, 30.5, 31.0, 35.8, 64.6, 124.1, 128.5, 130.8, 135.2, 
139.1, 151.6, 195.3. The sample of 43 was used to prepare 
44 without further purification. 
To the nitro compound 43 ( 4.22 g, 16.93 mmol) in acetic 
acid (150 mL) and water (31 mL) was added dropwise 40 
TiCli10%)/HCl (216 g, 169.3 mmol), and the final solution 
was strirred vigorously (7 h, RT). The new mixture was 
cooled (0° C.), and NaOH (30%, 600 mL) was added. The 
aqueous layer was extracted (EtOAc, 8x150 mL), and the 
combined organic layers were washed with water (2x70 mL) 45 
and saturated NaHCO3 (2x100 mL). The solution was then 
dried (Na2SO4). Evaporation of the solvent give 2.97 g 
(80%) of amine 44 [(8-amino-4,4-dimethylchroman-6-yl) 
methyl ketone] as a red thick oil. IR (KBr) 3449, 3338 
(N-H), cm-1 ; 1H NMR (DCC13) ll 1.37 [s, 6 H, C(CH3)2 ], 50 
1.85 [t, 2 H, C(CH2)], 2.52 [s, 3 H, COCH3], 3.84 [s, 2 H, 
NH2 ], 4.30 [t, 2 H, OCH2 ], 7.15 [d, 1 H, Ar-H], 7.3[d, 1 
H, Ar-H]. 13C NMR (DCCl3) ppm 26.1, 30.7, 37.1, 63.4, 
112.0, 117.9, 129.8, 130.9, 135.5, 145.7, 197.6. The com-
pound 44 was used without further purification to prepare 45 55 
and 46. 
7.85. Found: C, 59.07; H, 5.58; N, 10.13; S, 7.72. 
EXAMPLE X 
2,2,4,4-Tetramethyl-6-(2-propylamino )thiochroman 
( 47), [ {Methylethyl)(2,2,4,4,7-pentamethyl-(3H-
benzo[3,4-e ]thian-6-yl) }amino][( 4-nitrophenyl) 
amino]methane]-1-thione (48), and Ethyl 4-{[N-
Methylethyl)-N-(2,2,4,4-tetramethyl(3H-benzo[3,4-
e ]thian-6-yl))carbamoyl]amino }benzoate ( 49) 
A mixture of 6 (1.50 g, 6.78 mmol), dry acetone (0.589 g, 
10.16 mmol), titanium IV isopropoxide (1.93 g, 6.78 mmol), 
and ethanol (6 mL) was stirred for 18 h. To the yellow 
mixture was added portionwise sodium cyanoborohydride 
(8.51 g, 13.5 mmol) over 3 min, and the resulting mixture 
was stirred for 12 h. After cooling to 0° C., the reaction was 
quenched with aqueous ammonia (2 N, -15 mL), and the 
solid was filtered out. The solvent was evaporated to an oil 
which was partitioned between water and ether (3x40 mL). 
The combined organics were washed with brine and dried 
(N a2 SO 4). Evaporation of the solvent gave an oil which was 
subjected to flash chromatography over silica gel with 
hexanes:EtOAc (10:1) and yielded a thick red oil 47 (1.5 g, 
67%). IR (neat) 3395 (N-H) cm-1 ; 1H NMR (DCC13) Ii 
1.20 [d, 6 H, 1=6.3 Hz, NC(CH3)2 ], 1.36 [s, 6 H, C(CH3)2 ], 
1.38 [s, 6 H, C(CH3)2 ] 1.89 [s, 2 H, CH2 ], 3.30 [s, 1 H, NH], 
3.58 [q, 1 H, 1=6.3 Hz, CH], 6.38 [q, 1 H, Ar-H], 6.65 [d, 
1 H, Ar-H], 6.94 [d, 1 H, Ar-H]. This sample of 47 was 
used immediately to prepare 48 and 49. 
A solution of 47 (0.410 g, 1.56 mmol) in THF (6 mL) was 
treated dropwise with 4-nitrophenylisothiocyanate (0.309 g, 
To a solution of amine 44 (0.310 g, 1.41 mmol) in THF 
(6 mL) was added dropwise a solution of ethyl 
4-isocyanatobenzoate (0.97 g, 1.56 mmol) in THF at -5° C. 
under N2 . After the mixture had warmed to room 
temperature, it was stirred overnight. Evaporation of the 
solvent gave an oil which crystallized when treated with 
H2 CC12 :pentane as a white solid 45 (0.260 g, 45%), mp 
194--195° C. IR (KBr) 3409, 3295 (N-H), 1730 (C=O), 
1659 (ester C=O) cm-1 ; 1H NMR (DCC13) ll 1.28 [s, 6 H, 
C(CH3)2 ], 1.38 [t, 3 H, 1=7.1 Hz, CH3], 1.75 [t, 2 H, 1=5.2 
Hz, CH2 ], 2.57 [s, 3 H, COCH3], 4.12 [t, 2 H, 1=5.2 Hz, 
60 1.71 mmol) in THF (11 mL) at 0-5° C. under N2 . The 
reaction mixture was allowed to warm to room temperature 
and was then stirred overnight. Evaporation of the solvent 
gave a light yellow solid which was recrystallized 
(pentane:H2 CC12 , 4:1) to yield 48 (0.330 g, 48%) as a yellow 
65 solid, mp 142-143° C. IR (KBr) 3366 (N-H) cm-1 ; 1H 
NMR (DCC13) Ii 1.15 [d, 6 H, 1=6.7 Hz, NC(CH3)2 ], 1.41 [s, 
6 H, CC(CH3)2 ], 1.47 [s, 6 H, CC(CH3)2 ], 2.01 [s, 2 H, 
US 6,586,460 Bl 
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CH2 ], 5.92 [m, 1 H, NCH], 6.90 [m, 1 H, Ar-H], 7.06 [s, 
1 H, NH], 7.18 [s, 1 H,Ar-H], 7.28 [d, 1 H,Ar-H], 7.56 
[ m, 2 H, Ar-H], 8.13 [ m, 2 H, Ar-H]; 13C NMR (DCC13 ) 
ppm 20.87, 31.50, 32.72, 35.60, 42.42, 51.81, 53.43, and 
Ar-C [123.8, 124.0, 126.8, 128.1, 129.4, 132.7, 135.6, 5 
144.1, 144.9, 145.0], and 179.41 [C=S]. Calcd for 
C23H29N3 O2S2 : C, 62.27; H, 6.59; N, 9.47; S, 14.46. Found: 
1.00 [d, 3 H, 1=6.7 Hz, NCCH3 ], 1.23 [d, 3 H, 1=6.5 9 Hz, 
NCCH3 ], 1.32 [s, 6 H, C(CH3) 2 ], 1.53 [s, 6 H, C(CH3) 2 ], 
3.63 [ s, 2 H, CH2 ], 3.84 [ s, 3 H, OCH3 ], 5.86 [ m, 1 H, NCH], 
6.84 [s, 1 H, Ar-H(5)], 6.95[s, 1 H, Ar-H(8)], 7.05 [s, 1 
H, NH], 7.53 [d, 2 H, 1=9.l Hz, Ar-H(13), Ar-H(17)], 
8.24 [s, 2 H, 1=9.1 Hz, Ar-H(14), Ar-H(16)]; 13C NMR 
(DCC13) ppm 19.23, 21.44, 26.83, 26.91, 29.62, 29.83, 
34.37, 52.70, 55.57, 70.44, 74.54, andAr-C [108.9, 122.7, 
123.9, 124.2, 127.3, 135.3, 144.0, 145.4, 146.0] 153.7, and 
180.1 [C=S]. Calcd for C24H31N3 O4 S: C, 63.00; H, 6.83; 
N, 9.18; S, 7.01. Found: C, 62.78; H, 6.94; N, 9.06; S, 6.91. 
C, 62.32; H, 6.64; N, 9.49; S, 14.42. 
A solution of 47 (0.500 g, 1.90 mmol) in THF (11 mL) 
was treated dropwise with ethyl 4-isocyanatobenzoate 10 
(0.400 g, 2.09 mmol) in THF (10 mL) at 0-5° C. under N2 . 
The reaction mixture was allowed to warm to room tem-
perature and was then stirred overnight. Removal of the 
solvent afforded a white solid which was recrystallized 
(pentane:CH2 Cl,2 , 8:1) to give 49 (0.290 g, 34%) as a white 15 
solid, mp 92-93° C. IR (KBr) 3388 (N-H), 1708 (C=O), 
1680 cm-1; 1H NMR Ii 1.10 [d, 6 H. 1=6.7 Hz, NC(CH3) 2 ], 
1.39 [m, 9 H, C(CH3 ) 2 and CH2 CH3 ], 1.48 [s, 6 H, C(CH3 ) 
EXPERIMENTAL PROCEDURES AND 
RESULTS 
The following explanation of experimental procedures 
used to evaluate the compounds of the present invention and 
the results obtained therefrom serve to further illustrate the 
2 ], 2.01 [s, 2 H, CH2 ], 4.32 [q, 2 H, 1=7.1 Hz, OCH2 ], 4.92 
] 6 20 [ 1 H NH] 6 93 [ 1 H 20 invention and the utility of the inventive compounds. m, 1 H, 1=6.9 Hz NCH , . s, , , . m, , 
Ar-H], 7.22 [m, 2 H, Ar-H], 7.30 [m, 2 H, Ar-H], 7.90 
[m, 2 H, Ar-H]; 13C NMR (DCC13 ) ppm 14.32, 21.40, 
31.52, 32.73, 35.51, 42.31, 46.65, 53.63, 60.61, and Ar-C 
[117.8, 124.2, 128.1, 129.1, 129.4, 130.6, 133.2, 134.3, 
143.3, 144.4], 153.5 [NCONH], and 166.3 [C=O]. Calcd 25 
for C26H34N2 O3S: C, 68.69; H, 7.54; N, 6.16; S, 7.05. 
Found: C, 68.84; H, 7.76; N, 6.11; S, 6.78. 
General Method for Growth Inhibition Assay 
To illustrate the general and useful biological activity of 
the heteroarotinoids described in this invention, selected 
compounds were screened for ability to inhibit the growth of 
three ovarian cancerous cell lines, namely Caov, SKOV, and 
OVCAR cell lines, three cervical cell lines (Cervix HPV-Wt 
p53, Cervix HPV-Mut p53, and Cervix HPV-Mut p53), and EXAMPLE XI 
As a representative example of a compound related to 
those in Example X, but initiating from 29 rather than from 
6, we illustrate the synthesis of 51 via 29-50-51. 
A solution of the amine 29 (1.0 g, 4.25 mmol), acetone 
(0.37 g, 6.37 mmol), titanium (VI) isopropoxide (Aldrich, 
1.20 g, 4.25 mmol), and ethanol ( 4 mL) was stirred for 24 
h. To the resulting yellow solution was added sodium 
cyanoborohydride (0.534 g, 8.50 mmol) portionwise over 10 
min, and the resulting solution was stirred for 24 h. The flask 
was cooled to 0° C., and the reaction was quenched with 
aqueous ammonia (10 mL, 2 N). The resulting inorganic 
precipitate was filtered and washed with ether. The filtrate 
was then concentrated in vacuo, cooled (8° C.), and refil-
tered. The aqueous layer was extracted with ether (3x30 
mL). The combined organic layers were washed with brine 
and then dried (Na2 SO4). Evaporation of the solvent in 
vacuo gave amine 50 as a light yellow oil. Crystallization 
followed, and then recrystallization (H3C-OH) and stand-
ing in a freezer gave 50 (0.900 g, 76%) as a white solid, mp 
90-92° C. IR (KBr) 3385 (N-H), cm-1 ; 1H NMR (DCC13 ) 
ll 1.22 [d, 6 H, 1=6.3 Hz, NC(CH3) 2 ], 1.23 [s, 6 H, C(CH3) 2 ], 
1.51 [s, 6 H, C(CH3 ) 2 ], 3.55 [m, 1 H, NCH], 3.59 [s, 2 H, 
CH2 ], 3.83 [s, 3 H, OCH3 ], 3.92 [s, 1 H, NH], 6.22 [s, 1 H, 
Ar-H], 6.63 [s, 1 H, Ar-H]; 13C NMR (DCC13 ) ppm 
22.96, 27.07, 29.82, 33.31, 43.78, 55.31, 71.23, 75.03, and 
Ar-C[105.7, 106.7, 129.6, 133.7, 135.2, 145.4]. The inter-
mediate 50 was used immediately and without further puri-
fication for the preparation of 51. 
To a solution of amine 50 (0.400 g, 1.44 mmol) in THF 
(8 mL) was added dropwise 4-nitrophenylisothiocyanate 
(0.286 g, 1.59 mmol) in THF (10 mL) at -5° C. under N2 . 
The reaction mixture was allowed to warm to room tem-
perature and was then stirred overnight. Evaporation of the 
solvent afforded an yellow oil which crystallized upon 
standing and was recrystallized [pentane:CH2 Cl2 , 5:1] to 
give 51 (0.300 g, 45%) as a light yellow solid, mp 176° C. 
(dee). IR (KBr) 3374 (N-H), cm-1 ; 1H NMR (DCC13) Ii 
30 one vulvar (Vulvar HPV-Mut p53) cell line as shown in 
Tables I-III. The cell lines and the technology have been 
previously described [See Journal of Medicinal Chemistry, 
1999, Vol. 42, pages 3602-3614 in an article entitled 
"Synthesis, Structure-Activity Relationships, and RAR 
35 y-Ligand Interactions of Nitrogen Heteroarotinoids" by A 
Dhar, S. Liu, 1. Klucik, K. D. Berlin, M. M. Madler, S. Lu, 
R. T. Ivey, D. Zacheis, C. W. Brown, E. C. Nelson, P. 1. 
Birckbichler, and D. M. Benbrook], but the general tech-
nique was slightly modified. Cultures of the cancerous cells 
40 were plated in volumes of 150 µL in 96-well microtiter 
plates at concentrations of 2000-4000 cells/well, depending 
upon the cell line used. Retinoids were added the next day 
at 4x the concentrations in 50 µL of media resulting in 1, 2, 
3, 4, 5, 7, and 10 µM final concentrations of each retinoid. 
45 Control cultures were treated with the same volume of 
DMSO. After 3 days of treatment, the cell density in each 
well was determined by fixing the cells in trichloroacetic 
acid followed by staining the cytoplasmic proteins with 
sulforhoamine B (SRB). After rinsing, the SRB was solu-
50 bilized in Tris-HCl, and the optical density of each culture 
was determined with a MR600 microtiter plate reader. Each 
experiment was performed in triplicate, and the three values 
of each treatment were averaged. The average OD of the 
treated cultures was divided by that of the control cultures 
55 treated with solvent alone. To determine the percent growth 
inhibition, this ratio was subtracted from 1 and multiplied by 
100. Tables I, II, and III contain representative examples of 
the inhibition of growth by the inventive heteroarotinoids of 
the cancerous cell lines investigated at two independent 
60 concentrations (1 and 10 µM). As standards for comparison 
purposes, trans-retinoic acid (t-RA), 9-cis-retinoic acid (9-c-
RA), 13-cis-retinoic acid (13-c-RA), and 
4-hydroxyretinamide ( 4-HPR) were added in parallel 
experiments along with the heteroarotinoids and with dim-
65 ethyl sulfoxide (DMSO) as the solvent. For convenience, the 
data in Tables II and III are duplicated and ranked according 
to tumor type. 
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TABLE I 
PERCENTAGE GROWTH INHIBITION INDUCED BY A THREE-DAY TREATMENT OF 
SEVEN CANCEROUS CELL LINES WITH 10 µM HETEROARTOTINOIDS COMPARED 
TO 9-c-RA 
Cervix Cervix Cervix Vulva Ovarian Ovarian Ovarian 
HPV+ HPV- HPV- HPV- HPV- HPV- HPV-
Cell Type Wtp53 Mut p53 Mut p53 Mut p53 Mut p53 Mut p53 Null p53 
Cell Line SiHa HT-3 C-33A SW962 CAOV-3 OVCAR-3 SK-OV-3 
Agent 
11 72 82 87 98 80 94 100 
12 62 65 84 95 95 74 90 
13 66 85 76 96 98 77 94 
9-c-RA 24 47 44 31 27 28 30 
TABLE II 
PERCENTAGE OF GROWTH INHIBITION BY HETEROAROTINOIDS WITH THREE-ATOM LINKERS IN THREE CELL 
LINES AT 1 MICROMOLAR CONCENTRATION 
1 gM CONCENTRATION OF THE HETEROAROTINOID 
Ranked by CAOV-3 Ranked by SK-OV-3 Ranked by OVCAR-3 
CAOV- SKOV- OVCAR- CAOV- SKOV- OVCAR- CAOV- SKOV- OVCAR-
HET 3 3 3 HET 3 3 3 HET 3 3 3 
15 19.85 -1.86 8.91 13-c-RA 28.5 9.8 40 15.24 1.82 15.47 
24 17.55 1.86 -2.16 9-c-RA 23.0 6.2 39 14.39 3.60 14.37 
16 15.33 -1.67 10.20 34 22.2 2.2 21 9.5 12.1 
40 15.24 1.82 15.47 19 16.3 9.6 20 14.7 10.3 
39 14.39 3.60 14.37 20 14.7 10.3 16 15.33 -1.67 10.20 
23 11.36 -0.79 -0.19 18 10.5 10.1 18 10.5 10.1 
32 9.88 -1.99 4.31 35 10.3 5.6 13-c-RA 28.5 9.8 
38 8.79 -2.39 9.48 36 10.2 8.0 19 16.3 9.6 
41 7.58 -2.72 7.18 21 9.5 12.2 38 8.79 -2.39 9.48 
45 7.18 -4.18 9.20 t-RA 8.8 6.0 45 7.18 -4.18 9.20 
31 6.88 -1.42 3.83 4-HPR 7.2 2.7 15 19.85 -1.86 8.91 
46 3.85 -1.53 8.57 39 14.39 3.60 14.37 33 3.79 1.65 8.81 
33 3.79 1.65 8.81 14 -4.00 3.58 -6.70 46 3.85 -1.53 8.57 
DMSO 0.03 0.08 -0.10 17 3.0 6.6 36 10.2 8.0 
14 -4.00 3.58 -6.70 24 17.55 1.86 -2.16 41 7.58 -2.72 7.18 
22 -9.97 1.09 4.07 40 15.24 1.82 15.47 17 3.0 6.6 
21 9.5 12.1 33 3.79 1.65 8.81 9-c-RA 23.0 6.2 
20 14.7 10.3 22 -9.97 1.09 4.07 tRA 8.8 6.0 
18 10.5 10.1 DMSO 0.03 0.08 -0.10 35 10.3 5.6 
13-c-RA 28.5 9.8 23 11.36 -0.79 -0.19 32 9.88 -1.99 4.31 
19 16.3 9.6 31 6.88 -1.42 3.83 22 -9.97 1.09 4.07 
36 10.2 8.0 46 3.85 -1.53 8.57 31 6.88 -1.42 3.88 
17 3.0 6.6 16 15.33 -1.67 10.20 4-HPR 7.2 2.7 
9-c-RA 23.0 6.2 15 19.85 -1.86 8.91 34 22.2 2.2 
t-RA 8.8 6.0 32 9.88 -1.99 4.31 DMSO 0.03 0.08 -0.10 
35 10.3 5.6 38 8.79 -2.39 9.48 23 11.36 -0.79 -0.19 
4-HPR 7.2 2.7 41 7.58 -2.72 7.18 24 17.55 1.86 -2.16 
34 22.2 2.2 45 7.18 -4.18 9.20 14 -4.00 3.58 -6.70 
t-RA = trans-retinoic acid; 
9-c-RA = 9-cis-retinoic acid; 
13-c-RA = 13-cis-retinoic acid; 
4-HPR - 4-hydroxyphenylretinamide; 
DMSO - dimethyl sulfoxide 
TABLE III 
PERCENTAGE OF GROWTH INHIBITION BY HETEROAROTINOIDS WITH THREE-ATOM LINKERS IN THREE CELL 
LINES AT 1 MICROMOLAR CONCENTRATION 
10 gM CONCENTRATION OF THE HETEROAROTINOID 
Ranked by CAOV-3 Ranked by SK-OV-3 Ranked by OVCAR-3 
CAOV- SKOV- OVCAR- CAOV- SKOV- OVCAR- CAOV- SKOV- OVCAR-
HET 3 3 3 HET 3 3 3 HET 3 3 3 
22 40.14 22 40.14 41 61.94 45.45 81.71 
16 83.22 52.81 74.05 17 65.3 64.9 31 30.81 27.41 80.59 
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TABLE III-continued 
PERCENTAGE OF GROWTH INHIBITION BY HETEROAROTINOIDS WITH THREE-ATOM LINKERS IN THREE CELL 
LINES AT 1 MICROMOLAR CONCENTRATION 
10 gM CONCENTRATION OF THE HETEROAROTINOID 
Ranked by CAOV-3 Ranked by SK-OV-3 Ranked by OVCAR-3 
CAOV- SKOV- OVCAR- CAOV- SKOV- OVCAR- CAOV- SKOV- OVCAR-
HET 3 3 3 HET 3 3 3 HET 3 3 3 
41 61.94 45.45 81.71 4-HPR 64.9 43.1 16 83.22 52.81 74.05 
24 53.11 7.98 26.53 16 83.22 52.81 74.05 17 65.3 64.9 
45 42.75 20.02 47.25 41 61.94 45.45 81.71 33 40.04 15.60 52.61 
33 40.04 15.60 52.61 19 33.3 33.2 45 42.75 20.02 47.25 
40 37.84 9.27 33.74 31 30.81 27.41 80.59 20 12.1 47.1 
31 30.81 27.41 80.59 45 42.75 20.02 47.25 46 -5.35 0.25 43.15 
23 17.77 7.67 2.75 9-c-RA 16.0 5.3 4-HPR 64.9 43.1 
32 16.30 -5.01 18.33 33 40.04 15.60 52.61 15 -9.56 9.83 40.90 
14 6.12 0.43 5.45 20 12.1 47.1 22 40.13 
DMSO -0.04 0.06 0.00 15 -9.56 9.83 40.90 40 37.84 9.27 33.74 
46 -5.35 0.25 43.15 40 37.84 9.27 33.74 19 33.3 33.2 
15 -9.56 9.83 40.90 18 8.5 18.7 24 53.11 7.98 26.53 
39 -14.65 -10.01 15.45 24 53.11 7.98 26.53 21 -13.9 19.5 
38 -16.12 -7.70 8.96 23 17.77 7.67 2.75 18 8.5 18.7 
17 65.3 64.9 t-RA 6.0 -3.0 32 16.3 -5.01 18.33 
20 12.1 47.1 34 6.0 30.5 39 -14.65 -10.01 15.45 
4-HPR 64.9 43.1 14 6.12 0.43 5.45 38 -16.12 -7.70 8.96 
19 33.3 33.2 46 -5.35 0.25 43.15 35 -14.3 6.1 
21 -13.9 19.5 DMSO -0.04 0.06 0.00 14 6.12 0.43 5.45 
18 8.5 18.7 36 -3.1 4.7 9-c-RA 16.0 5.3 
35 -14.3 6.1 32 16.30 -5.01 18.33 36 -3.1 4.7 
9-c-RA 16.0 5.3 38 -16.12 -7.70 8.96 23 17.77 7.67 2.75 
36 -3.1 4.7 39 -14.65 -10.01 15.45 DMSO -0.04 0.06 0.00 
t-RA 6.0 -3.0 21 -13.9 19.5 t-RA 6.0 3.0 
35 -14.3 6.1 
t-RA = trans-retinoic acid; 
9-c-RA = 9-cis-retinoic acid; 
13-c-RA = 13-cis-retinoic acid; 
4-HPR - 4-hydroxyphenylretinamide; 
DMSO - dimethyl sulfoxide 
The overall applicability of the heteroarotinoids is dem-
onstrated against the variety of tumor types with different 
genetic defects (Table I). The majority of cervix tumors 
40 
contain Human Papillomavirus (HPV) DNA, and heteroa-
The greater than 74% of growth inhibition in the 
OVCAR-3 cell line in the three-day treatment experiment 
(Table I) indicated that cell loss occurred in the cultures 
treated with heteroarotinoids 11-13. Optimal chemothera-
peutic agents will selectively kill tumor cells by inducing a 
natural form of cell death which is called "apoptosis". Toxic 
agents kill both normal and tumor cells via a nonspecific 
process known as "necrosis". To differentiate between apo-
ptosis and necrosis in heteroarotinoid-treated cultures, a 
flow cytometric assay was employed. Treated cultures were 
stained withAnnexin-V-Flous and propidium iodide, and the 
rotinoids 11, 12, and 13 were active against cell lines 
regardless of the presence (HPV +) or absence (HPV-) of 
HPV (Table I). The majority of tumors of any type contain 
p53 mutations, and heteroarotinoids 11, 12, 13 were quite 45 
active against both cell lines containing normal (Wt p53) 
and mutant (Mut p53) cells. 
It is clear that there is a gradient of activity with respect 
to the inhibitory ability of growth of the cell lines by the 
various heteroarotinoids (Tables I-III). There is also a 
difference observed in terms of inhibition at the two different 
concentrations of agents employed (Tables II and III). The 
changes in substituents within the structures could not have 
been predicted to elicit the activity displayed by the het-
eroarotinoids. It is also remarkable that the activity shown 
by a significant number of these heteroarotinoids exceeded 
the activity of the controls, all of which have been and are 
still used in clinics. For example, at the 1 µM concentration 
(Table II) the inhibition of growth of the OVCAR cell line 
50 intensities of the stains are quantitated with Flow Cytometry. 
The Annexin-V-Flous binds to phosphatidyl serine on the 
exterior of apoptosing cells. This assay is specific for 
apoptosing cells because phosphatidyl serine is normally 
55 
located on the inner membrane of the cells, a situation 
whereby the serine derivative cannot be bound by Annexin. 
by heteroarotinoid 40 exceeded that of 13-c-RA by about 60 
40%, that of 9-c-RA by about 120%, that oft-RA by about 
120%, and that of 4-HPR by more than 1200%. Thus, the 
heteroarotinoids are proved active in inhibiting the growth 
of the exemplar cell lines. 
Apoptosis Assay 
However, during apoptosis, phosphatidyl serine is translo-
cated to the outer membrane. The Flous moiety emits a 
signal that can be detected and quantitated by Flow Cytom-
etry. In contrast, propidium iodide is taken up by necrotic 
cells that have lost membrane integrity. In this study, t-RA 
was used as a control for the non-apoptotic retinoids, and 
4-HPR was used as a control for the apoptotic retinoids. The 
results are shown in Table IV. 
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TABLE IV 
PERCENTAGE OF INDUCTION OF APOPTOSIS IN SW962 
VULVAR CARCINOMA CULTURES BY AGENT 11 AND 4-HPR 
BUTNOTt-RA 
Compound 
Days 11 4-HPR t-RA 
0 3 3 3 
6.11 1.67 2.53 
2 11.42 3.6 
3 39.06 17.28 1.25 
4 48.79 4.5 
7 47.5 3.51 
In another experiment, the ovarian carcinoma cell line 
OVCAR-3 was grown in organotypic culture. After one 
week, the cultures were treated with 1 µM solution of 
heteroarotinoids 11, 12, and 13, or with the same volume of 
DMSO (solvent), for two weeks. Both 9-c-RA and 4-HPR 
were used as controls. At the end of the time, the cultures 
were fixed in sectioned, and stained with the TUNNEL assay 
to detect apoptosing cells. An experienced pathologist quan-
titated the percent of apoptosing cells by light microscopic 
examination. The results are shown in Table V. 
TABLE V 









4-HPR - 4-hydroxyphenylretinamide; 








Apoptosis, or cell death, was observed in selected het-
eroarotinods that exhibited the strongest inhibition of growth 
in the cancerous cell lines included in Tables II and III. Thus, 
the percentages of cells which underwent apoptosis in 
treated cultures correlated significantly with growth inhibi-
tion (R=0.9749, p=0.0017). Representative agents 11, 12, 
and 13 were chosen for more detailed apoptosis studies 
(Tables IV and V). It is clear that agent 11 in the SW962 
vulvar cell (Table IV) was superior to the clinically used 
agent 4-HPR in the apoptosis experiment and exceeded the 
value for the common standard t-RA. With the OVCAR-3 
cell line (Table V), both 11 and 13 were as effective as 
4-HPR while 12 was only slightly less effective in inducing 
apoptosis. Thus, the heteroarotinoids possess a range of 
abilities to induce apoptosis of these cancerous cells. 
In Vivo Tumor Xenographs 
30 
before implantation into mice. Animals were injected with 
3.5xl06 cells into right scapular region with a 24-gauge 
needle/1 mL tuberculin syringe (Becton Dickinson, 
Rutherford, N.J.). Twenty four hours after tumor 
5 implantation, animals were randomized into four treatment 
groups of 5 animals each. Retinoids were administered daily 
p.o. beginning 35 days after tumor implantation with a 
20-gauge intragastric feeding tube (Popper & Sons, New 
Hyde Park, N.Y.), 5 days/week, at doses of 10 mg/kg/day in 
0.1 mL of super refined sesame oil (Corda, Inc., Parisppany, 
N.J.). Tumors were measured with calipers weekly, and 
tumor volumes were calculated using the formula: volume= 
lengthxwidthxheigth. Animal weights and clinical signs of 
10 
overall health status and cutaneous toxicities were recorded 
15 weekly. Agents 11 and 13 were evaluated against the 4-HPR 
standard. FIG. 1 illustrates the overall changes in tumor 
volumes found in the mice in these experiments. As can be 
seen in FIG. 1, both 11 and 13 inhibited tumor growth to 
similar extents. After 15 days of treatment, the sizes of the 
20 tumors in the animal group treated with 11 and 13 were 
significantly smaller than in the control group treated with 
sesame oil alone (t-test: P<0.05). The animals were moni-
tored daily for signs of toxicity, such as skin eczema and 
bone fractures, but none were observed. This is added 
25 evidence that these heteroarotinoids are strong candidates 
for cancer chemotherapy. 
Liver Toxicity 
Although no skin or bone toxicity signs were seen in the 
30 
mice employed in the study, some retinoids are known to 
cause liver toxicity which requires laboratory assays to 
quantify [See "Adverse Effects of Retinoids" in Medical 
Toxicolgy Adverse Drug Exp., volume 3, 1988, pp 213-219, 
by M. David, E. Hodak, and N. J. Lowe]. Toxic compounds 
35 
can induce livers to release enzymes called serum 
transaminases, such as alanine aminotransferase (ALT). The 
assay for ALT is the most universally accepted clinical 
laboratory marker used to evaluate hepatic toxicity induced 
by pharmaceuticals [See "Serum Transferase Elevations as 
40 
Indicators or Hepatic Injury Following the Administration of 
Drugs", Reg. Tox. Pharm., volume 27, 1998, pp 119-130, by 
D. E. Amacher]. At the end of the treatment period, blood 
was drawn from each animal. Plasma was separated by 
centrifugation and stored at - 70° C. The activity of ALT was 
45 
determined in aliquots of plasma by standard spectrophoto-
metric enzymatic techniques which were based upon the 
reduction of pyruvate by lactate dehydrogenase [See "Aged 
Mice are Resistant to the Hepatotoxic Effects of Endotoxin 
and Galactosamine" in Exp. Mol. Pathology, volume 59, 
50 
1993, pp 27-37]. The method measures the disappearance of 
NADH from time of incubation at 37° C. The activities have 
been expressed in µm/Liter/min (Table VI). Two different 
amounts of plasma were utilized in each assay to assure the 
measurement of the maximum rate. Eleven mice in the 
55 
control and treated groups exhibited ALT activities that were 
in the normal range of 28 to 184 µL/min as determined by 
the commercial suppliers of the mice (Charles River 
Laboratories, Wilmington, Mass.). 
To demonstrate biological activity in vivo, an ovarian 
xenograph mouse model was employed. Thirty female athy-
mic nu/nu mice (Charles Rivers Laboratories, Wilmington, 
Mass.) were housed in a laminar flow room under sterile 
conditions at 83-85° F. The mice were quarantined for one 60 
week prior to the beginning of the study and were allowed 
access to autoclaved food (Purina 5001 mouse/rat sterilized 
diet, St. Louis, Mo.) and water ad libitum. Then OVCAR-3 
cells in log phase growth were harvested by trypsinization, 
resuspended in RPMI culture medium, and centrifuged at 65 
3000 rpm for 10 min. The pellets were then resuspended in 
RPMI culture medium at a concentration of 7xl06 cells/mL 
TABLE VI 
ALT ACTIVITY IN PLASMA OF MICE TREATED WITH 11 13 




ALT ACTIVITY (um/Liter/Min) 
118.5 ± 153.4 
64.5 ± 40.3 
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TABLE VI-continued 
ALT ACTIVITY IN PLASMA OF MICE TREATED WITH 11, 13, 




ALT ACTIVITY (um/Liter/Min) 
149.7 ± 140.9 
103.0 ± 60.3 
There were no statistically significant differences between 
the ALT activities in the different treatment groups (Table 
VI, t-test: P>0.05). All numbers were in the normal range 
( 63 to 307 µm/Liter/Min) of ALT values for the species of 
mouse utilized. All liver sections were assessed by an 
experienced pathologist in a blinded manner. The degree of 
necrosis was very mild in all animals. Thus, the heteroaro-
tinoids 11 and 13, as well as 4-HPR, do not appear to induce 
significant liver toxicity. 
Receptor Activation 
Both heteroarotinoids 11 and 13 resemble 4-HPR in that 
all are potent inducers of apoptosis. Since 4-HPR acts 
through a receptor-independent mechanism, agent 11 was 
evaluated for ability to transactivate a RARE reporter 
through endogenous receptors in the SW962 vulvar carci-
noma cell line. The general method has been described [See 
"Biologically Active Heteroarotinoids Exhibit Anticancer 
Activity and Decreased Toxicity", Journal of Medicinal 
Chemistry Volume 40, 1997, pp 3576-3583, by D. M. 
Benbrook, M. M. Madler, L. W. Spruce, P. J. Birckbichler, 
32 
compounds capable of inducing apoptosis contained the 
more rigid three atom linkers. The more rigid apoptotic 
hetereroarotinoids appear to hold greater promise as chemo-
prevention agents, since they induce similar levels of growth 
5 inhibition as the growth inhibitory retinoids, while inducing 
significantly greater levels of apoptosis. The fact that the 
inventive heteroarotinoids and known heteroarotinoids 
induce similar levels of growth inhibition indicates that the 
new compounds are significantly improved over prior com-
10 pounds in that they retain the same anti-cancer activities (i.e. 
growth inhibition and induction of differentiation) while 
exhibiting additional more potent anti-cancer activities (i.e. 
apoptosis). 
Furthermore, the inventive heteroarotinoids are signifi-
cantly different than previously described heteroarotinoids 
15 in that they act in a receptor-independent mechanism, while 
prior known compounds activated the retinoid receptors. 
Chemosensitization 
The compounds of the present invention also find advan-
tage over the standard retinoids, including retinoic acid and 
20 4-HPR as chemosensitization agents. In another study, ova-
rian carcinoma cultures, including cisplatin-resistant 
cultures, were trypsinized and plated in microtiter plates at 
a concentration of 1000 cells per well. A series of natural and 
synthetic retinoids, including exemplar heteroarotinoids 
25 with the novel three atom linker, at a concentration of 5 µM 
were added to triplicate wells in the microtiter plates twenty-
four hours later. The same volume of DMSO used to 
administer the compounds were added to the control cul-
tures. After three days of treatment, a range of cisplatin 
30 concentrations were added to the wells. After one hours of E. C. Nelson, S. Subramanian, G. M. Weerasekare, J. B. 
Gale, M. K. Patterson, Jr., B. Wang, W. Wang, S. Lu, T. C. 
Rowland, P. DiSivestro, C. Lindamood, D. L. Hill, and K. D. 
Berlin]. No induction of the retinoid receptors was observed 
although 9-cis-RA casued a 4 to 10 fold induction of 
RARE-driven transcription in the same experiment with the 35 
SW962 cell line. To further demonstrate the lack of 
transactivation, 11 was again assessed for ability to activate 
each of the retinoic acid receptors in a CV-1 co-transfection 
assay. No transactivation was observed in these experiments 
exposure, the media and retinoid drugs were replenished. 
Cell survival was quantitated using the MTS assay 
(Promega). It was found that cisplatin-resistant cultures 
were sensitized and that the synthetic heteroarotinoids were 
more effective than retinoic acid and 4-HPR. Thus, the 
present invention contemplates the process of sensitizing 
cells to cisplatin therapy and combined cisplatin and radia-
tion therapy using the inventive heteroarotinoids. 
Once the results were obtained that 5 micromolar con-
centrations of 4-HPR and heteroarotinoids prevented the 
growth increase induced by a range of cisplatin concentra-
tions in the OVCAR-3 cisplatin-resistant ovarian carcinoma 
cell line, a further experiment was conducted to determine 
whether the inventive compounds were better than the 
in which 9-cis-RA did demonstrate a 2 to 4 fold induction. 40 
Thus, these heteroarotinoids do not appear: to activate the 
common retinoid receptors. 
Statistical Analysis 
All data were entered into Microsoft Excel 5.0, which was 
used to perform t-tests and to derive correlation coefficients. 
Thus, it may be appreciated that heteroarotinoids 11 and 
13, administered at the maximum tolerated dose (MTD) for 
t-RA (10 mg/kg/day), decreased xenograph tumor growth 
and did not cause toxicity to the skin, bones, or liver. These 
results, and the other results discussed above, clearly dem-
onstrate that the heteroarotinoids described herein are as 
effective as the current retinoid standard 4-HPR for ovarian 
cancer chemoprevention. The inventive compounds appear 
to have advantages over the current retinoid standards 
insofar as they demonstrate the ability to induce apoptosis at 
clinically achievable concentrations. Current understanding 
of retinoid chemoprevention mechanisms is complicated by 
the finding that promising compounds, such as 4-HPR, 
induce apoptosis through retinoic acid receptor-independent 
mechanisms only at concentrations above those achieved in 
clinical chemoprevention trials. At lower concentrations 
( ~ 1 µM) however, 4-HPR acts similar to classical retinoids 
45 industry standard 4-HPR at the clinically achievable con-
centration of 1 micromolar. In this regard, the cisplatin 
resistant OVCAR-3 cell line was pre-treated with a concen-
tration of 1 µM of the indicated retinoids for 3 days, and then 
exposed to cisplatin at the concentration detected in tumors 
50 of treated patients ( 40 µM or 1 µg/ml). The cisplatin con-
centration used was the concentration detected in tumors of 
treated patients (40 µM or 1 µg/ml). After one hour of 
cisplatin exposure, the cisplatin was removed and the cul-
tures were grown in the presence of 1 µM of the indicated 
55 retinoids for an additional 3 days. The number of living cells 
present was then determined using the MTS (3-( 4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2H-
tetrazolium inner salt) assay (Promega). In the MTS assay, 
metabolically active cells reduce the MTS compound to an 
60 aqueous soluble formazan resulting in an absorbance that 
can be measured at 490 nm (Promega Technical Bulletin 
No.169). The optical density at 490 nm (OD490) of the 
MTS-treated cultures is then determined and used as a by inducing differentiation through a receptor-dependent 
mechanism. Comparison of the inventive heteroarotinoid 
structures with their biologic activities revealed that the 65 
compounds containing more flexible connecting ester link-
ages were unable to induce apoptosis. In contrast, all of the 
measure of the number of living cells in each well. The 
percent growth is determined by dividing the OD490 of the 
treated cultures by the OD490 of the untreated control 
cultures. 
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As indicated in FIG. 2, at a 1 micromolar concentration, 
the inventive heteroarotinoids, but not 4-HPR are effective. 
All of the bars in FIG. 2 represent the average and standard 
deviations of an experiment performed in triplicate. Each bar 
represents cultures treated with cisplatin in the absence of 5 
retinoid (DMSO), or in the presence of 1 µM 4HPR or 
heteroarotinoids 11, 12, 13, 16 and 24. The culture treated 
with cisplatin alone (DMSO) is not growth inhibited because 
OVCAR-3 is a cisplatin-resistant cell line. 
While the invention has been described with a certain 10 
degree of particularity, it is understood that the invention is 
not limited to the embodiment(s) set for herein for purposes 
of exemplification, but is to be limited only by the scope of 
the attached claim or claims, including the full range of 
equivalency to which each element thereof is entitled. 
What is claimed is: 





w I ✓,:::; 
R Z 
in which: 
G denotes H or CH3 ; 
R denotes H, CH3 , or OCH3 ; 
Q denotes H or i-C3H7 ; 
W denotes O or S; and 
or 
Z denotes NO2 , CO2Et, CO2-n-C4H9 or SO2NH2 . 












































































13. The compound according to claim 2, wherein the 
compound is in the form of the substituted 6-isomer thereof. 
14. The compound according to claim 3, wherein the 
65 compound is in the form of the substituted 6-isomer thereof. 
15. The compound according to claim 4, wherein the 
compound is in the form of the substituted 6-isomer thereof. 
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G denotes H or CH3 ; 
R denotes H, CH3 , or OCH3 ; 
Q denotes H or i-C3H7 ; 
W denotes O or S; and 
or 
Z denotes NO2 , CO2Et, CO2-n-C4H9 or SO2NH2 . 












































23. A compound selected from those of the formula: 
in which: 
G denotes H, CH3 , C(O)-CH3 ; 
R denotes H, CH3 , or OCH3 ; 
W denotes O or S; 
Q denotes H or i-C3 H7 ; and 
Z denotes NO2 , CO2Et or CO2-n-C4H9 . 
24. A method for sensitizing tumor cells in a host to 
treatment by a chemotherapy agent, comprising administer-
40 ing to the host a tumor sensitizing effective amount of one 
or more compounds selected from the group consisting of 
the compounds of claims 1, 16, or 23. 
25. A method for treating a tumor bearing host, compris-
ing administering to the host a therapeutically effective 
45 amount of one or more compounds selected from the group 
consisting of the compounds of claims 1, 16 or 23. 
26. A method of inhibiting tumor growth or regrowth in 
a prospective tumor host comprising administering to the 
host a tumor inhibiting effective amount of one or more 
50 compounds selected from the group consisting of the com-
pounds of claims 1, 16 or 23. 
27. A pharmaceutical composition, comprising one or 
more compounds selected from the group consisting of the 
compounds of claims 1, 16 or 23 in combination with a 
55 pharmaceutically acceptable, non-toxic, inert delivery 
vehicle. 
* * * * * 
